Document:

Fourth Amended and Restated Investor Rights Agreement

 Exhibit 10.1 

TABLE OF CONTENTS 
  

							
	 	 	 	  	 	  	Page
	1.	 	Restrictions on Transferability; Registration Rights	  	1
				
		 	1.1	  	Certain Definitions	  	1
		 	1.2	  	Restrictions	  	5
		 	1.3	  	Requested Registration	  	6
		 	1.4	  	Registration on Form S-3	  	8
		 	1.5	  	Company Registration	  	10
		 	1.6	  	Registration Procedures	  	11
		 	1.7	  	Information by Holder	  	13
		 	1.8	  	Indemnification	  	13
		 	1.9	  	Expenses of Registration	  	16
		 	1.10	  	Rule 144 Reporting	  	16
		 	1.11	  	Transfer of Registration Rights	  	17
		 	1.12	  	Limitations on Subsequent Registration Rights	  	17
		 	1.13	  	Procedure for Underwriter Cutbacks	  	17
		 	1.14	  	Standoff Agreement	  	18
		 	1.15	  	Termination of Rights	  	18
			
	2.	 	Right of First Refusal	  	18
				
		 	2.1	  	Right of First Refusal	  	18
		 	2.2	  	Assignment of Right of First Refusal	  	19
		 	2.3	  	Termination of Right of First Refusal	  	19
			
	3.	 	Affirmative Covenants of the Company	  	20
				
		 	3.1	  	Financial Information	  	20
		 	3.2	  	Operating Plan and Budget	  	20
		 	3.3	  	Inspection	  	21
		 	3.4	  	Stock Vesting	  	21
		 	3.5	  	Key Man Life Insurance	  	21
		 	3.6	  	Directors’ & Officers’ Liability	  	21
		 	3.7	  	Board Committees	  	21
		 	3.8	  	Actions Requiring Board Approval	  	21
		 	3.9	  	Actions Requiring a Waiver of the Preferred	  	22
		 	3.10	  	Company Confidential Information	  	23
		 	3.11	  	Observer Rights	  	23
		 	3.12	  	Termination of Covenants	  	25
			
	4.	 	Acknowledgement	  	25
			
	5.	 	Miscellaneous	  	25

  

 i 

							
				
		 	5.1	  	Governing Law	  	26
		 	5.2	  	Successors and Assigns	  	26
		 	5.3	  	Entire Agreement	  	26
		 	5.4	  	Notices	  	26
		 	5.5	  	Delays or Omissions	  	27
		 	5.6	  	Dispute Resolution Fees	  	27
		 	5.7	  	Counterparts	  	27
		 	5.8	  	Severability	  	27
		 	5.9	  	Titles and Subtitles	  	27
		 	5.10	  	Amendment and Waiver	  	27
		 	5.11	  	Effect of Amendment or Waiver	  	28
		 	5.12	  	Termination of Prior Agreement	  	28
		 	5.13	  	Waiver	  	28
		 	5.14	  	Rights of Investors	  	28
		 	5.15	  	Aggregation of Stock	  	28
		 	5.16	  	Specific Performance	  	28
		 	5.17	  	Jurisdiction and Venue; Waiver of Jury Trial	  	28

 EXHIBIT A - Schedule of Investors

 EXHIBIT B - Schedule of Founders 

 FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

This Fourth Amended and Restated Investor Rights Agreement (this “Agreement”) is made as of August 6,
2010, among Complete Genomics, Inc., a Delaware corporation (the “Company”), the stockholders and warrantholders listed on Exhibit A hereto (each, an “Investor” and collectively, the
“Investors”) and the stockholders and founders of the Company listed on Exhibit B hereto (each, a “Founder” and collectively, the “Founders”). 

RECITALS 

The Company and certain of the Investors have entered into a Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) of even date herewith pursuant to which the Company wants to sell to such Investors and such Investors want to purchase from the Company shares of the Company’s Series E Preferred Stock. One condition to such
Investors’ obligations to purchase shares of the Company’s Series E Preferred Stock under the Purchase Agreement is that the Company and such Investors enter into this Agreement in order to provide such Investors with certain rights to
register shares of the Company’s Common Stock issuable upon conversion of the Series E Preferred Stock held by such Investors, certain rights to receive information pertaining to the Company, and a right of first offer with respect to certain
issuances by the Company of its securities. The Company wants to induce such Investors to purchase shares of Series E Preferred Stock pursuant to the Purchase Agreement by agreeing to the terms and conditions set forth herein. 

The Company, the Investors and the Founders previously entered into that certain Third Amended and Restated Investor Rights Agreement
dated August 12, 2009, as amended November 6, 2009 and February 16, 2010 (the “Prior Agreement”). The parties to the Prior Agreement desire to amend and restate the Prior Agreement in its entirety, and to
accept the rights and restrictions created in this Agreement in lieu of the rights and restrictions contained in the Prior Agreement. Section 5.10 of the Prior Agreement vested the authority to amend the Prior Agreement in the Company and the
Holder or Holders (as defined in the Prior Agreement) holding, in the aggregate, more than sixty percent (60%) of the outstanding shares of Common Stock issued or issuable pursuant to conversion of the Shares (as defined in the Prior
Agreement). The Holders (as defined in the Prior Agreement) holding more than sixty percent (60%) of the outstanding shares of Common Stock issued or issuable pursuant to conversion of the Shares (as defined in the Prior Agreement) are entering
into this Agreement, making this Agreement binding upon all of the parties to the Prior Agreement 
 AGREEMENT 

The parties agree as follows: 

1.    Restrictions on Transferability; Registration Rights. 

1.1        Certain Definitions.  As used in this Agreement, the following terms
have the following respective meanings: 
 “Board” means the board of directors of the Company.

 “Commission” means the Securities and Exchange Commission or any
other federal agency at the time administering the Securities Act. 
 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, or any similar successor federal statute, and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

“Form S-3 Initiating Holders” means any Holder or Holders who in the aggregate hold not less than two and one
half percent (2.5%) of the Registrable Securities then outstanding and who propose to register securities, the aggregate offering price of which exceeds $5,000,000. 

“Gold Hill” shall mean Gold Hill Venture Lending 03, L.P. 

“Gold Hill Warrant” shall mean the warrant issued to Gold Hill in connection with the Loan and Security
Agreement by and among the Company, SVB and Gold Hill, dated as of September 21, 2006. 
 “Holder”
means (i) any Investor or Founder holding Registrable Securities; (ii) SVB and Gold Hill; provided, however, that SVB and Gold Hill shall not be deemed Holders for purposes of Sections 1.3, 2 and 3 of this Agreement except with respect to
the Shares of Series C Preferred Stock held by Gold Hill and the Common Stock issuable upon conversion thereof; and (iii) any person holding Registrable Securities to whom the rights under this Agreement have been transferred in accordance with
Section 1.11 hereof. 
 “Initiating Holders” means any Holder or Holders who in the aggregate hold
not less than forty percent (40%) of the Registrable Securities then outstanding and who propose to register securities, the aggregate offering price of which, net of underwriting discounts and commissions, exceeds $5,000,000. 

“IPO” means the first public offering of the Common Stock of the Company to the general public that is affected
pursuant to a registration statement filed with, and declared effective by, the Commission under the Securities Act. 

“Major Investors” means Essex Woodlands Health Ventures Fund VIII, L.P., Essex Woodlands Health Ventures Fund
VIII-A, L.P. and Essex Woodlands Health Ventures Fund VIII-B, L.P. (any of them, “Essex”), OrbiMed Associates III, LP and Caduceus Private Investments III, LP (either, “OrbiMed”), Highland Capital
Management, L.P. (“Highland”), Prospect Venture Partners III, L.P., OVP Venture Partners VI, L.P., Enterprise Partners VI, LP, SCV-CG, LLC (“Sands”) and any New Investor (as defined in the Purchase
Agreement) that is designated in writing as a “Major Investor” by the Board of Directors in its sole discretion and Genentech, Inc., together with their respective affiliates; provided, however, that Genentech, Inc. shall not be a Major
Investor for the purposes of Sections 2 or 3 hereof. 
 “New Securities” means any shares of capital
stock of the Company, including Common Stock and Preferred Stock, whether authorized or not, and rights, options, or warrants to purchase said shares of capital stock, and securities of any type whatsoever (including debt instruments) that are, or
may become, convertible into capital stock; provided, however, that the 
  

 2 

 
term “New Securities” does not include (i) the issuance of Common Stock or Preferred Stock upon the conversion of any bonds, debentures, notes or other evidence of indebtedness,
and any warrants, shares or any other securities convertible into, exercisable for, or exchangeable for Common Stock, including Preferred Stock, or for Preferred Stock (collectively, “Convertible Securities”), outstanding as
of the date hereof; (ii) the issuance of shares as approved by the Board (including at least three of the Preferred Directors) of Common Stock (or options to purchase shares of Common Stock) to employees, officers, directors or consultants of
the Company under equity incentive plans, programs or agreements approved by the Board (not including the reissuance of shares repurchased by the Company from employees or consultants of the Company); (iii) the issuance of shares of Common
Stock or Convertible Securities to lenders, financial institutions, equipment lessors, or real estate lessors to the Company in connection with commercial credit arrangements, equipment financings, commercial property leases or similar transactions
approved by the Board; (iv) the issuance of shares of Common Stock or Convertible Securities pursuant to (A) the acquisition of another business by the Company by merger, purchase of substantially all of the assets or shares, or other
reorganization whereby the Company or its shareholders own not less than a majority of the voting power of the surviving or successor business or (B) the acquisition of technology or other intellectual property by outright purchase or exclusive
license, in each case, provided that such transaction is approved by the Board; (v) the issuance of shares of Common Stock in connection with a Qualified IPO; (vi) the issuance of shares of Common Stock or Convertible Securities in
connection with strategic partnership transactions approved by the Board; (vii) the issuance of shares pursuant to stock splits, stock dividends or similar transactions; or (viii) securities issued pursuant to the Purchase Agreement.

 “Other Stockholders” means persons other than Holders who, by virtue of agreements with the Company,
are entitled to include their securities in certain registrations hereunder. 
 “Preferred Director”
has the meaning set forth in the Restated Certificate. 
 “Pro Rata Portion” means the ratio that
(x) the sum of the number of shares of the Company’s Common Stock held by an Investor immediately prior to the issuance of New Securities, assuming conversion of the Shares but excluding any other security of the Company exercisable for,
or convertible into, Common Stock, bears to (y) the sum of the total number of shares of the Company’s Common Stock then outstanding, assuming conversion of the Shares but excluding any other security of the Company exercisable for, or
convertible into, Common Stock then outstanding. 
 The terms “register”,
“registered” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of the
effectiveness of such registration statement. 
 “Qualified IPO” shall have the meaning set forth in
the Restated Certificate. 
 “Registration Expenses” shall mean all expenses incurred by the Company in
complying with Sections 1.3, 1.4, and 1.5 hereof, including, without limitation, all registration, qualification, listing and filing fees, printing expenses, escrow fees, fees and disbursements of

  

 3 

 
counsel for the Company, fees and disbursements of one counsel for all of the Holders registering securities in any given registration, blue sky fees and expenses, and the expense of any
special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company), but shall not include Selling Expenses. 

“Registrable Securities” shall mean (i) shares of Common Stock issued or issuable pursuant to the
conversion of the Shares, (ii) other (x) shares of Common Stock held prior to the IPO by holders of Shares, (y) shares of Common Stock issuable upon the exercise of warrants held prior to the IPO by holders of Shares and
(z) shares of Common Stock issuable upon the conversion of shares of Preferred Stock issuable upon the exercise of warrants held prior to the IPO by holders of Shares, (iii) shares of Series B Preferred Stock issued upon exercise of the
SVB Warrant or the Gold Hill Warrant; provided, however, that such shares shall not be deemed Registrable Securities and the holders thereof shall not be deemed Holders for purposes of Sections 1.3, 2 and 3 of this Agreement; (iv) any Common
Stock of the Company issued as a dividend or other distribution with respect to or in exchange for or in replacement of the shares referenced in clauses (i) and (ii) above; and (v) solely for the purposes of Section 1.5, shares
of Common Stock issued or issuable to the Founders and to Callida Genomics, Inc.; provided, however, that shares of Common Stock or other securities shall only be treated as Registrable Securities if and so long as they have not been
(A) sold to or through a broker or dealer or underwriter in a public distribution or a public securities transaction, (B) transferred in a transaction pursuant to which the registration rights are not also assigned in accordance with
Section 1.11 hereof, or (C) with respect to each Holder, all such shares held by such Holder become eligible for sale immediately under Rule 144 of the Securities Act (or any successor rule). 

“Restricted Securities” shall mean the securities of the Company required to bear the legend set forth in
Section 1.2 hereof. 
 “Rule 144” means Rule 144 as promulgated by the Commission under the
Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

“Rule 145” means Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended
from time to time, or any similar successor rule that may be promulgated by the Commission. 
 “Securities
Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder or any similar federal statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect
at the time. 
 “Selling Expenses” shall mean all underwriting discounts, selling commissions and stock
transfer taxes applicable to the securities registered by the Holders and all fees and disbursements of counsel for any Holder, other than the fees and disbursements of one counsel for all of the Holders registering securities in any given
registration as provided in the definition of “Registration Expenses” above. 
  

 4 

 “Shares” means the Company’s Series A Preferred Stock, Series
B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock. 
 “SVB
Warrant” shall mean the warrant that was transferred from Silicon Valley Bank to SVB Financial Group and that was originally issued to Silicon Valley Bank in connection with the Loan and Security Agreement by and among the Company,
Silicon Valley Bank and Gold Hill, dated as of September 21, 2006. 

1.2        Restrictions. 

(a)        Each Holder agrees not to make any disposition of all or any portion of the
Registrable Securities unless and until the transferee has agreed in writing for the benefit of the Company to be bound by this Section 1.2 and by Section 1.14 hereof, provided and to the extent such Sections are then applicable, and
(i) there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement, or (ii) such Holder shall have notified the
Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and, if reasonably requested by the Company, such Holder shall have furnished the Company
with an opinion of counsel or other evidence reasonably satisfactory to the Company, that such disposition will not require registration under the Securities Act. Notwithstanding the foregoing, no such registration statement or opinion of counsel
shall be necessary for a transfer by a Holder which is (A) a partnership to its partners or retired partners in accordance with partnership interests, (B) a limited liability company to its members or former members in accordance with
their interest in the limited liability company, (C) a corporation to its shareholders in accordance with their interests in the corporation, (D) to the Holder’s family member or trust for the benefit of an individual Holder, or
(E) to any of its affiliates (including but not limited to an affiliated fund managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under common control with such
manager or managing member or general partner or management company, each an “Affiliated Entity”), provided in all cases enumerated in clauses (A) – (E) that the transferee is subject to the terms of this
Section 1.2 and Section 1.14 as if such transferee were an original Holder hereunder. Each Holder consents to the Company making a notation on its records and giving instructions to any transfer agent of the Restricted Securities in order
to implement the restrictions on transfer established in this Section 1.2. 

(b)        Each certificate representing Registrable Securities shall be stamped or otherwise
imprinted with legends substantially in the following forms (in addition to any legend required under applicable state securities laws or the Company’s charter documents): 

“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR OTHER

  

 5 

 
EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.” 

“THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY
AND THE SHAREHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.” 

(c)        The Company shall promptly reissue unlegended certificates at the request of any
Holder thereof if the Holder shall have obtained an opinion of counsel or other evidence reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be disposed of without registration,
qualification, or legend. 
 1.3         Requested Registration. 

(a)        Request for Registration.  If the Company shall receive from
Initiating Holders a written request that the Company effect any registration, qualification, or compliance, the Company will: 

(i)        promptly deliver written notice of the proposed registration, qualification, or
compliance to all other Holders; and 
 (ii)        as soon as practicable, use its
best efforts to effect such registration, qualification, or compliance (including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable blue sky or other state securities
laws, and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or such
portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request delivered to the Company
within twenty (20) days after delivery of such written notice from the Company; provided, however, that the Company shall not be obligated to take any action to effect any such registration, qualification, or compliance pursuant
to this Section 1.3: 
 (A)        Prior to the earlier of: (i) two
(2) years following the date of this Agreement, and (ii) six months following the effective date of an IPO; 

(B)        After the Company has effected two (2) such registrations pursuant to this
Section 1.3, such registrations have been declared or ordered effective, and the securities offered pursuant to such registrations have been sold; 

(C)        During the period starting with the date sixty (60) days prior to the
Company’s estimated date of filing of, and ending on a date one hundred and eighty (180) days after the effective date of, a registration initiated by the Company; provided that the Company (i) delivers notice of the Company’s
intent to effect such registration 
  

 6 

 
to the Holders within thirty (30) days after the Company’s receipt of the request of the Initiating Holders and is actively employing in good faith all reasonable efforts to cause such
registration statement to become effective and that the Company’s estimate of the date of filing such registration statement is made in good faith, and (ii) may not defer its registration obligations under Section 1.3 for more than an
aggregate of Two Hundred Forty (240) days in any twelve (12) month period pursuant to this Section 1.3(a)(ii)(C) and/or Section 1.3(a)(ii)(E); 

(D)        In any particular jurisdiction in which the Company would be required to execute a
general consent to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(E)        If in the good faith judgment of the Board, such registration would be seriously
detrimental to the Company and the Board concludes, as a result, that it is essential to defer the filing of such registration statement at such time, and the Company thereafter delivers to the Initiating Holders a certificate, signed by the
President or Chief Executive Officer of the Company, stating that in the good faith judgment of the Board it would be seriously detrimental to the Company or its stockholders for a registration statement to be filed in the near future, then the
Company’s obligation to use its best efforts to register, qualify, or comply under this Section 1.3 shall be deferred for a period, not to exceed sixty (60) days from the delivery of the written request from the Initiating Holders,
during which such filing would be seriously detrimental; provided, however, that the Company (i) may not utilize this right more than twice in any twelve (12) month period, and (ii) may not defer its registration
obligations under Section 1.3 for more than an aggregate of Two Hundred Forty (240) days in any twelve (12) month period pursuant to this Section 1.3(a)(ii)(E) and/or Section 1.3(a)(ii)(C); 

(F)        If the Initiating Holders do not request that such offering be firmly underwritten by
underwriters selected by the Initiating Holders (subject to the consent of the Company, which consent will not be unreasonably withheld or delayed); or 

(G)        If the Initiating Holders propose to dispose of shares of Registrable Securities
which may be immediately registered on Form S-3 pursuant to a request made under Section 1.4 hereof. 
 Subject to the
foregoing clauses (A) through (G), the Company shall file a registration statement covering the Registrable Securities so requested to be registered as soon as practicable after receipt of the request or requests of the Initiating Holders. The
registration statement filed pursuant to the request of the Initiating Holders may, subject to the provisions of Sections 1.3(c) hereof, include other securities of the Company with respect to which registration rights have been granted, and may
include securities being sold for the account of the Company. For the avoidance of doubt, the Company may utilize its right to defer registration under Section 1.3(a)(ii)(E) in two consecutive sixty (60) day periods in any twelve
(12) month period to defer a requested registration for up to one hundred twenty (120) days (subject to the limitation in Section 1.3(a)(ii)(E)(ii)). 

(b)        Underwriting.  If the Initiating Holders request that such offering
be firmly underwritten by underwriters selected by the Initiating Holders (subject to the 
  

 7 

 
consent of the Company, which consent will not be unreasonably withheld), the right of any Holder to registration pursuant to this Section 1.3 shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. A Holder may elect to include in such underwriting all or a part of the Registrable Securities held
by such Holder. 
 (c)        Procedures.  The Initiating Holders
shall, on behalf of all Holders, offer to include such securities in the underwriting and may condition such offer on their acceptance of the applicable provisions of this Section 1 (including without limitation Section 1.14). The Company
shall (together with all Holders or other persons proposing to distribute their securities through such underwriting) enter into and perform its obligations under an underwriting agreement in customary form with the managing underwriter selected for
such underwriting by the Initiating Holders holding a majority of the then outstanding shares held by all Initiating Holders (which managing underwriter shall be reasonably acceptable to the Company). Notwithstanding any other provision of this
Agreement, if the managing underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, the number of shares to be included in the underwriting or registration shall be
allocated among all participating Holders thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each participating Holder. In no event shall any
Registrable Securities be excluded from such underwriting unless all other securities are first excluded from such offering. If any person who has requested inclusion in such registration as provided above disapproves of the terms of the
underwriting, such person shall be excluded therefrom by written notice delivered by the Company or the managing underwriter. Any Registrable Securities and/or other securities so excluded or withdrawn shall also be withdrawn from registration.

 1.4        Registration on Form S-3. 

(a)        Qualification on Form S-3.  After the IPO, the Company shall use its
best efforts to qualify for registration on Form S-3 or any comparable or successor form. To that end the Company shall register (whether or not required by law to do so) its Common Stock under the Exchange Act in accordance with the provisions of
the Exchange Act following the effective date of the first registration of any securities of the Company on Form S-1 or any comparable or successor form or forms. 

(b)        Request for Registration on Form S-3.  After the Company has
qualified for the use of Form S-3, if the Company shall receive from Form S-3 Initiating Holders a written request that the Company effect a registration on Form S-3 the Company will: 

(i)        promptly deliver written notice of the proposed registration to all other Holders;
and 
 (ii)        as soon as practicable, use its best efforts to effect such
registration, qualification, or compliance (including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable blue sky or other state securities laws, and appropriate
compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as may be so 

 

 8 

 
requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of
the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request delivered to the Company within twenty (20) days after delivery of such written notice from the Company; provided,
however, that the Company shall not be obligated to take any action to effect any such registration, qualification, or compliance pursuant to this Section 1.4: 

(A)        After the fifth anniversary of an IPO; 

(B)        After the Company has effected two (2) such registrations pursuant to this
Section 1.4 during any twelve (12) month period, such registrations have been declared or ordered effective and the securities offered pursuant to such registrations have been sold; 

(C)        During the period starting with the date sixty (60) days prior to the
Company’s estimated date of filing of, and ending on a date one hundred and eighty (180) days after the effective date of, a registration initiated by the Company; provided that the Company (i) delivers notice of the
Company’s intent to effect such registration to the Holders within thirty (30) days after the Company’s receipt of the request of the Form S-3 Initiating Holders and is actively employing in good faith all reasonable efforts to cause
such registration statement to become effective and that the Company’s estimate of the date of filing such registration statement is made in good faith, and (ii) may not defer its registration obligations under Section 1.4 for more
than an aggregate of Two Hundred Forty (240) days in any twelve (12) month period pursuant to this Section 1.4(b)(ii)(C) and/or Section 1.4(b)(ii)(E); 

(D)        In any particular jurisdiction in which the Company would be required to execute a
general consent to service of process in effecting such registration, qualification, or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(E)        If in the good faith judgment of the Board, such registration would be seriously
detrimental to the Company and the Board concludes, as a result, that it is essential to defer the filing of such registration statement at such time, and the Company thereafter delivers to the Form S-3 Initiating Holders a certificate, signed by
the President or Chief Executive Officer of the Company, stating that in the good faith judgment of the Board it would be seriously detrimental to the Company or its stockholders for a registration statement to be filed in the near future, then the
Company’s obligation to use its best efforts to register, qualify, or comply under this Section 1.4 shall be deferred, for a period not to exceed sixty (60) days from the date of delivery of the written request from the Form S-3
Initiating Holders, during which such filing would be seriously detrimental; provided, however, that the Company (i) may not utilize this right more than twice in any twelve (12) month period, and (ii) may not defer its
registration obligations under Section 1.4 for more than an aggregate of Two Hundred Forty (240) days in any twelve (12) month period pursuant to this Section 1.4(b)(ii)(E) and/or Section 1.4(b)(ii)(C). For the avoidance of
doubt, the Company may utilize its right to defer registration under Section 1.4(a)(ii)(E) in two consecutive sixty (60) day periods in any 

 

 9 

 
twelve (12) month period to defer a requested registration for up to one hundred twenty (120) days (subject to the limitation in Section 1.4(a)(ii)(E)(ii)). 

(c)        Underwriting; Procedure.  If a registration requested under this
Section 1.4 is for an underwritten offering, the provisions of Sections 1.3(b) and 1.3(c) shall apply to such registration. Registrations effected pursuant to this Section 1.4 shall not be counted as demands for registration(s) effected
pursuant to Sections 1.3 or 1.5, respectively. 
 1.5        Company
Registration. 
 (a)        Notice of Registration.  If the
Company shall determine to register any of its securities, either for its own account or the account of a security holder or holders other than (A) a registration pursuant to Sections 1.3 or 1.4 hereof, (B) a registration relating solely
to employee benefit plans, (C) a registration relating solely to a Rule 145 transaction, or (D) a registration on any registration form that does not permit secondary sales, the Company will: 

(i)        promptly deliver to each Holder written notice thereof; and 

(ii)        use its best efforts to include in such registration (and any related qualification
under blue sky laws or other compliance), except as set forth in Section 1.5(b) below, and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests made by any Holder and delivered to the
Company within twenty (20) days after the written notice is delivered by the Company. Such written request may include all or a portion of a Holder’s Registrable Securities. 

(b)        Underwriting; Procedures.  If the registration of which the Company
gives notice is for a registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 1.5(a)(i). In such event, the right of any Holder to registration
pursuant to this Section 1.5 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute
their securities through such underwriting shall (together with the Company and the other holders distributing their securities through such underwriting) enter into and perform their obligations under an underwriting agreement in customary form
with the managing underwriter selected for such underwriting by the Company. Notwithstanding any other provision of this Section 1.5, if the managing underwriter determines that marketing factors require a limitation of the number of shares to
be underwritten, the managing underwriter may (subject to the limitations set forth below) exclude Registrable Securities from, or limit the number of Registrable Securities to be included in, the registration and underwriting. The Company shall so
advise all holders of securities requesting registration, and the number of shares of securities that are entitled to be included in the registration and underwriting shall be allocated as set forth in Section 1.13. If any person who has
requested inclusion in such registration as provided above disapproves of the terms of the underwriting, such person shall be excluded therefrom by written notice delivered by the Company or the managing underwriter. Any Registrable

  

 10 

 
Securities and/or other securities so excluded or withdrawn shall also be withdrawn from registration. 

(c)        Right to Terminate Registration.  The Company shall have the right
to terminate or withdraw any registration initiated by it under this Section 1.5 prior to the effectiveness of such registration, whether or not any Holder has elected to include securities in such registration. 

1.6        Registration Procedures.  In the case of each registration,
qualification, or compliance effected by the Company pursuant to this Section 1, the Company will keep each Holder advised in writing as to the initiation of each registration, qualification, and compliance and as to the completion thereof and,
at its expense, the Company will use its best efforts to: 
 (a)        Prepare and
file with the Commission a registration statement with respect to such securities and use its best efforts to cause such registration statement to become and remain effective for at least one hundred eighty (180) days or until the distribution
described in the registration statement has been completed, whichever occurs first; provided, however, that (i) such 180-day period shall be extended for a period of time equal to the period the Holder refrains from selling any
securities included in such registration at the request of an underwriter of common stock or other securities of the Company, and (ii) in the case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a
continuous or delayed basis, such 180-day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Securities Act,
permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Securities Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment which
(A) includes any prospectus required by Section 10(a)(3) of the Securities Act or (B) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation
by reference of information required to be included in (A) and (B) above shall be contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration statement; 

(b)        Furnish to the Holders participating in such registration and to the underwriters of
the securities being registered such reasonable number of copies of the registration statement, preliminary prospectus, final prospectus, and such other documents as they may reasonably request in order to facilitate the public offering of such
securities; 
 (c)        Prepare and file with the Commission such amendments and
supplements to such registration statement and the prospectus used in connection with such registration statements as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by
such registration statement; 
 (d)        Notify each seller of Registrable Securities
covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as
then in effect, includes an untrue statement of a 
  

 11 

 
material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then
existing, and at the request of any such seller, prepare and furnish to such seller a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchaser of such
shares, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the
circumstances then existing; 
 (e)        Use its best efforts to register and qualify
the securities covered by such registration statement under such other securities or blue sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; 

(f)        Cause all such Registrable Securities to be listed on each securities exchange on
which similar securities issued by the Company are then listed; 
 (g)        Provide a
transfer agent and registrar for all Registrable Securities and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h)        Use its best efforts to furnish, at the request of any Holder requesting registration
of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold
through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated such date, of the counsel representing
the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable
Securities and (ii) a letter, dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public
offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities (to the extent the then-applicable standards of professional conduct permit said letter to be addressed to the Holders);

 (i)        In connection with any underwritten offering pursuant to a registration
statement filed pursuant to this Agreement, enter into and perform an underwriting agreement in form reasonably necessary to effect the offer and sale of Registrable Securities, provided such underwriting agreement contains reasonable and customary
provisions, and provided further that each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement; and 

(j)        Make available for inspection by any underwriter participating in any disposition
pursuant to such registration statement, and any attorney or accountant retained by any such underwriter (collectively, the “Inspectors”), all pertinent 

 

 12 

 
records and documents of the Company (collectively, the “Records”) as shall be reasonably necessary to enable them to exercise any applicable due diligence responsibility,
and cause the Company’s officers, directors, and employees to use good faith to supply such information as is reasonably requested by any such Inspector to meet such responsibilities. Records which the Company determines, in good faith, to be
confidential shall not be disclosed by the Inspectors unless (i) the disclosure of such Records is necessary to avoid or correct a misstatement or omission in the registration statement or (ii) the release of such Records is ordered
pursuant to a subpoena or other order from a court of competent jurisdiction. The relevant Inspector will, upon learning that disclosure of such Records is sought in a court of competent jurisdiction, give notice to the Company and allow the
Company, at the Company’s expense, to undertake appropriate action to prevent disclosure of the Records deemed confidential. 

1.7        Information by Holder.  The Holder or Holders of Registrable
Securities included in any registration shall furnish to the Company such information regarding such Holder or Holders, the Registrable Securities held by them, and the distribution proposed by such Holder or Holders as the Company may request in
writing and as shall be required in connection with any registration, qualification, or compliance referred to in this Section 1, and the refusal to furnish such information by any Holder or Holder shall relieve the Company of its obligations
in this Section 1 with respect to such Holder or Holders. Furthermore, the Company shall have no obligation with respect to any registration requested pursuant to Section 1.3 or Section 1.4 of this Agreement if, as a result of the
application of the preceding sentence, the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate
offering price required to originally trigger the Company’s obligation to initiate such registration as specified in the definition of “Initiating Holders” or “Form S-3 Initiating Holders,” whichever is applicable.

 1.8        Indemnification. 

(a)        To the extent permitted by law, the Company will indemnify and hold harmless each
Holder, each of its officers, directors, members, partners, legal counsel, and accountants, and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification, or
compliance has been effected pursuant to this Section 1, and each underwriter, if any, and each person who controls any underwriter within the meaning of Section 15 of the Securities Act, against all expenses, claims, losses, damages, or
liabilities (or actions, proceedings, or settlements in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any registration statement,
prospectus, offering circular, or other document (including any related registration statement, notification, or the like), or any amendment or supplement thereto, incident to any such registration, qualification, or compliance, or based on any
omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or any violation (or alleged violation)
by the Company of the Securities Act or Exchange Act, or any applicable state securities law, or any rule or regulation promulgated thereunder applicable to the Company in connection with any such registration, qualification, or compliance, and the
Company will reimburse each such Holder, each of its officers, directors, members, partners, legal counsel, and accountants, and 
  

 13 

 
each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with
investigating, preparing, defending, or settling any such claim, loss, damage, liability, or action, as such expenses are incurred, provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage,
liability, or expense arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by such Holder, controlling
person, or underwriter and stated to be specifically for use therein. It is agreed that the indemnity agreement contained in this Section 1.8 shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if
such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld or delayed). 

(b)        To the extent permitted by law, each Holder will, if Registrable Securities held by
such Holder are included in the securities as to which such registration, qualification, or compliance is being effected, indemnify the Company, each of its directors, officers, partners, legal counsel, and accountants, and each underwriter, if any,
of the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, and each other such Holder, each of their officers,
directors, members and partners, and each person controlling such Holder within the meaning of Section 15 of the Securities Act, against all claims, losses, damages, and liabilities (or actions in respect thereof) arising out of or based on any
untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any such registration statement, prospectus, offering circular, or other document, or any omission (or alleged omission) to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and such Holders, directors, officers, members, partners, legal counsel, and accountants, persons, underwriters,
or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action, as such expenses are incurred, in each case to the extent, but only to the
extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular, or other document in reliance upon and in conformity with written information
furnished to the Company by such Holder and stated to be specifically for use therein, provided, however, that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of any such claims, losses, damages, or liabilities
(or actions in respect thereof) if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld or delayed); and provided that that in no event shall any indemnity under this Section 1.8 (when
combined with any contribution under Section 1.8(d)) exceed the net proceeds received by such Holder in such offering. 

(c)        Each party entitled to indemnification under this Section 1.8 (the
“Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which
indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or
litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense, provided further,

  

 14 

 
however, that an Indemnified Party (together with all other Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with
the reasonable fees and expenses to be paid by the Indemnifying Party, if representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between such
Indemnified Party and any other party represented by such counsel in such proceeding; and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under
this Section 1 unless (and only to the extent) the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action. No Indemnifying Party, in the defense of any such claim or litigation,
shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a
release from all liability in respect to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably
required in connection with the defense of such claim and litigation resulting therefrom. 

(d)        If the indemnification provided for in this Section 1.8 is held by a court of
competent jurisdiction to be unavailable to an Indemnified Party with respect to any claim, loss, damage, liability, or expense referred to therein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall
contribute to the amount paid or payable by such Indemnified Party as a result of such claim, loss, damage, liability, or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and the
Indemnified party on the other in connection with the statements or omissions that resulted in such claim, loss, damage, liability, or expense, as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and
of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact related to information supplied by the Indemnifying Party or
by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. The Company and the Holders agree that it would not be just and equitable if
contribution pursuant to this Section 1.8 were based solely upon the number of entities from whom contribution was requested or by any other method of allocation which does not take account of the equitable considerations referred to above. In
no event shall any contribution by a Holder under this Section 1.8 (when combined with any indemnification under Section 1.8(b)) exceed the net proceeds received by such Holder in such offering. 

(e)        The amount paid or payable by an Indemnified Party as a result of the losses, claims,
damages, and liabilities referred to above in this Section 1.8 shall be deemed to include any legal or other expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any such action or claim, subject
to the provisions of Section 1.8(c). No person guilty of fraudulent misrepresentation (within the meaning of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

 (f)        Notwithstanding the foregoing, to the extent that the provisions on
indemnification and contribution contained in the underwriting agreement entered 
  

 15 

 
into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(g)        The obligations of the Company and Holders under this Section 1.8 shall survive
the completion of any offering of Registrable Securities in a registration statement. 

1.9        Expenses of Registration.  All Registration Expenses shall be borne
by the Company; provided, however, that if the Holders bear the Registration Expenses for any registration proceeding begun pursuant to Section 1.3 and subsequently withdrawn by the Holders registering shares therein, such
registration proceeding shall not be counted as a requested registration pursuant to Section 1.3. Furthermore, in the event that a withdrawal by the Holders is based upon material adverse information relating to the Company that is different
from the information known or reasonably available (upon request from the Company or otherwise) to the Holders requesting registration at the time of their request for registration under Section 1.3, such registration proceeding shall not be
counted as a requested registration pursuant to Section 1.3, even though the Holders do not bear the Registration Expenses for such registration. All Selling Expenses relating to securities registered on behalf of the Holders shall be borne by
the holders of the registered securities included in such registration pro rata on the basis of the number of shares so registered. 

1.10        Rule 144 Reporting.  With a view to making available the benefits
of certain rules and regulations of the Commission which may at any time permit the sale of the Restricted Securities to the public without registration after such time as a public market exists for the Common Stock of the Company, the Company
agrees to use its best efforts to: 
 (a)        Make and keep public information
available, as those terms are understood and defined in Rule 144, at all times after the effective date that the Company becomes subject to the reporting requirements of the Securities Act or the Exchange Act; 

(b)        File with the Commission in a timely manner all reports and other documents required
of the Company under the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 

(c)        So long as a Holder owns any Restricted Securities, to furnish to the Holder
forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of Rule 144 and of any other reporting requirements of the Securities Act and the Exchange Act (at any time after it has become subject to
such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents of the Company and other information in the possession of or reasonably obtainable by the Company as a Holder may
reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration. 

(d)        Take such action, including the voluntary registration of its Common Stock under
Section 12 of the Exchange Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as 

 

 16 

 
practicable after the end of the fiscal year in which the first registration statement filed by the Company for the offering of its securities to the general public is declared effective.

 1.11        Transfer of Registration Rights.  The rights to cause
the Company to register securities granted to any party hereto under Section 1 may be assigned by a Holder only to a transferee or assignee of the lesser of (i) all of such Holder’s Registrable Securities and (ii) Eighty-Three
Thousand Three Hundred Thirty-Three (83,333) shares of Registrable Securities (as appropriately adjusted for stock splits and the like) or, with respect to Registrable Securities that are Series C Preferred Stock, Series D Preferred Stock,
Series E Preferred Stock or shares of Common Stock issuable upon conversion of Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock, Sixteen Thousand Six Hundred Sixty-Seven (16,667) shares (as appropriately adjusted
for stock splits and the like), provided that the Company is given written notice at the time of or promptly after said assignment, stating the name and address of the transferee or assignee and identifying the securities with respect to
which such registration rights are being assigned, and, provided further, that the assignee of such rights agree in writing to be bound by the terms and conditions of this Agreement. Notwithstanding the foregoing, no such minimum share
assignment requirement shall be necessary for an assignment by a Holder which is (A) a partnership to its partners or retired partners in accordance with partnership interests, (B) a limited liability company to its members or former
members in accordance with their interest in the limited liability company, (C) a corporation to its shareholders in accordance with their interests in the corporation, (D) to the Holder’s family member or trust for the benefit of an
individual Holder, or (E) to any Affiliated Entity. 
 1.12        Limitations
on Subsequent Registration Rights.  From and after the date hereof, the Company shall not, without the prior written consent of Holders who in the aggregate hold more than sixty percent (60%) of the Common Stock then issued or
issuable upon conversion of the Shares, enter into any agreement granting any holder or prospective holder of any securities of the Company registration rights the terms of which are more favorable than the registration rights granted to holders of
Shares hereunder. 
 1.13        Procedure for Underwriter
Cutbacks.  In any circumstance in which all of the Registrable Securities and other shares of Common Stock of the Company with registration rights that have not been expressly subordinated to the rights under this Agreement (the
“Other Shares”) requested to be included in a registration pursuant to Section 1.5 on behalf of Holders or Other Stockholders cannot be so included as a result of limitations of the aggregate number of shares of
Registrable Securities and Other Shares that may be so included, the number of shares of Registrable Securities and Other Shares that may be so included shall be allocated among the Holders and Other Stockholders requesting inclusion of shares pro
rata based upon the total number of Registrable Securities or Other Shares held by such Holders and Other Stockholders, respectively; provided, however, that such allocation shall not operate to reduce the aggregate number of
Registrable Securities or Other Shares to be included in such registration if any Holder or Other Stockholder does not request inclusion of the maximum number of shares of Registrable Securities or Other Shares allocated to such Holder or Other
Stockholder pursuant to the above-described procedure, in which case the remaining portion of his allocation shall be reallocated among those requesting Holders and Other Stockholders whose allocations did not satisfy their requests pro rata on the
basis of total number of shares of 
  

 17 

 
Registrable Securities and Other Shares held by such Holders and Other Stockholders, and this procedure shall be repeated until all shares of Registrable Securities and Other Shares which may be
included in the registration on behalf of the Holders and Other Stockholders have been so allocated. The Company shall not limit the number of shares of Registrable Securities to be included in a registration pursuant to Section 1.5 in order to
include shares of stock issued to founders of the Company or to employees, officers, directors, or consultants pursuant to the Company’s equity incentive plans, or to otherwise hold shares of any other stockholder that are not Other Shares.
Notwithstanding the foregoing, the number of shares of Registrable Securities included in a registration pursuant to Section 1.5 of this Agreement shall not be reduced below twenty five percent (25%) of the securities included in such
registration unless such offering is the Qualified IPO. 
 1.14        Standoff
Agreement.  Each Holder agrees in connection with the Company’s IPO, upon request of the underwriters managing such IPO, not to sell, make any short sale of, loan, pledge or otherwise hypothecate or encumber, grant any option for
the purchase of, or otherwise dispose of any Registrable Securities (other than those included in the registration) without the prior written consent of such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty
(180) days from the effective date of such registration (or such longer period, not to exceed thirty-four (34) days after the expiration of the 180-day period as the underwriters or the Company shall request in order to facilitate
compliance with FINRA Rule 2711) as may be requested by such managing underwriters, provided that all directors, officers and holders of two percent (2%) or more of the Company’s outstanding capital stock are similarly bound. The
Company agrees not to (and shall not permit the underwriter to) release any other stockholder from any lock up agreement or covenant unless the Holders are also released on a proportionate basis relative to their respective ownership of securities.
The obligations described in this Section 1.14 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a
transaction on Form S-4 or similar forms that may be promulgated in the future. 

1.15        Termination of Rights.  The rights of any particular Holder to
cause the Company to register securities under Sections 1.3, 1.4, and 1.5 shall terminate with respect to such Holder upon the earlier to occur of (i) the five (5) year anniversary of the effective date of the IPO or (ii) when all
Registrable Securities held by such Holder may be sold immediately pursuant to Rule 144. 
 2.    Right
of First Refusal. 
 2.1         Right of First Refusal. 

(a)        Right of First Refusal.  Subject to the terms and conditions
contained in this Section 2.1, the Company hereby grants to each Major Investor the right of first refusal to purchase their Pro Rata Portion of any New Securities which the Company may, from time to time, propose to issue and sell, provided,
however, with respect to each Major Investor, that such Major Investor continues to hold any Shares or Common Stock issued upon conversion thereof. 
  

 18 

 (b)        Notice of Right.  In
the event the Company proposes to undertake an issuance of New Securities, it shall give each Major Investor written notice of its intention, describing the type of New Securities and the price and terms upon which the Company proposes to issue the
same. Each Major Investor shall have twenty (20) days from the date of delivery of any such notice to agree to purchase up to such Major Investor’s Pro Rata Portion of such New Securities, for the price and upon the terms specified in the
notice, by delivering written notice to the Company and stating therein the quantity of New Securities to be purchased. 

(c)        Right of Over-Allotment.  In the event that the Major Investors fail
to fully exercise the right of first refusal within such twenty- (20-) day period, each Major Investor fully exercising its right of first refusal shall be offered the right to purchase up to the remaining portion that the Major Investors failed to
exercise (the “Over-Allotment Shares”); provided, that if the Major Investors with such over-allotment right exercise such right for an aggregate number in excess of such Over-Allotment Shares, the Over-Allotment Shares shall
be allocated among them in accordance with their respective Pro Rata Portions (or in such other manner as such electing Major Investors agree). The Company will promptly notify those Major Investors fully exercising their rights of first refusal, in
writing, of the availability of Over-Allotment Shares, and each of the fully-exercising Major Investors shall have ten (10) days from the date of receipt of any such notice to agree to purchase up to such Over-Allotment Shares (subject to the
proviso in the preceding sentence). 
 (d)        Lapse and Reinstatement of
Right.  The Company shall have sixty (60) days following the twenty- (20-) day period described in Section 2.1(b) and the additional ten- (10-) day period described in Section 2.1(c) to sell or enter into an agreement
(pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within thirty (30) days from the date of said agreement) to sell the New Securities with respect to which the Major Investors’ right of first refusal
was not exercised, at a price and upon terms no more favorable to the purchasers of such securities than specified in the Company’s notice. In the event the Company has not sold the New Securities or entered into an agreement to sell the New
Securities within said sixty- (60-) day period (or sold and issued New Securities in accordance with the foregoing within thirty (30) days from the date of said agreement), the Company shall not thereafter issue or sell any New Securities
without first offering such securities to the Major Investors in the manner provided above. 

2.2        Assignment of Right of First Refusal.  The right of first refusal
granted hereunder may not be assigned or transferred, except that: (i) such right is assignable by each Major Investor to one or more Affiliated Entities, or to any wholly-owned subsidiary or parent of, or to any corporation or entity that is,
within the meaning of the Securities Act, controlling, controlled by, or under common control with, any such Investor; and (ii) such right is assignable between and among any Major Investors. 

2.3        Termination of Right of First Refusal.  The right of first refusal
granted under Section 2.1 of this Agreement shall expire upon the earlier of, and shall not be applicable to, (i) a Qualified IPO, or (ii) a Liquidation (as defined in the Restated Certificate). 

 

 19 

 3.    Affirmative Covenants of the Company.  The
Company hereby covenants and agrees, so long as any Major Investor holds Registrable Securities, as follows: 

3.1        Financial Information.  The Company will furnish to such Major
Investor the following reports: 
 (a)        As soon as practicable after the end of
each fiscal year, and in any event within one hundred twenty (120) days thereafter (or such longer period as is approved by the Board, including each of the Preferred Directors), audited consolidated balance sheets of the Company and its
subsidiaries, if any, as of the end of such fiscal year, and consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year, prepared in accordance with generally accepted accounting principles
consistently applied and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and certified by independent public accountants of national standing selected by the Company; 

(b)        As soon as practicable, but in any event within forty-five (45) days after the
end of each quarter of each fiscal year of the Company, unaudited consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of such quarterly period, and consolidated statements of income and cash flows of the Company
and its subsidiaries, if any, for such quarterly period, prepared in accordance with generally accepted accounting principles consistently applied and setting forth in each case in comparative form the figures for the corresponding quarterly periods
of the previous fiscal year and the figures projected by the Company’s annual budget, subject to changes resulting from normal year-end audit adjustments, all in reasonable detail and certified by the principal financial or accounting officer
of the Company, except such financial statements need not contain the notes required by generally accepted accounting principles; 

(c)        As soon as practicable after the end of each calendar month, and in any event within
thirty (30) days thereafter, consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of each calendar month setting forth in comparative form the results projected by the Company’s annual budget, and
consolidated statements of income and cash flow for such period and for the current fiscal year to date; 

(d)        As soon as practicable after the end of each fiscal quarter, a statement showing the
number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the quarterly period, and the number of common shares issuable upon conversion or
exercise of any outstanding securities convertible or exercisable for common shares and the exchange ratio or exercise price applicable thereto, all in sufficient detail as to permit the Major Investor to calculate its percentage equity ownership in
the Company. 
 3.2        Operating Plan and Budget.  As soon as
practicable upon approval or adoption by the Board, and in any event at least thirty (30) days prior to the end of each fiscal year, the Company will furnish the Major Investors with the Company’s budget and operating plan (including
projected balance sheets and profit and loss and cash flow statements, forecasts 
  

 20 

 
of revenues, expenses, significant projected milestones and projected cash position on a month-to-month basis) for the upcoming fiscal year. 

3.3        Inspection.  The Company shall permit each Major Investor, at such
Major Investor’s expense and upon reasonable notice given to the Company to visit and inspect the Company’s properties, to examine its books of account and other records (and make copies and take extracts therefrom), and to discuss the
Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by such Major Investor. 

3.4        Stock Vesting.  All stock and stock options issued to employees,
directors, consultants and other service providers after the date of this Agreement will be subject to vesting at a rate of 25% one year after the vesting commencement date, with monthly vesting thereafter for the next thirty six (36) months,
unless otherwise approved by the Board. Each agreement pursuant to which such stock or stock option is issued or granted shall include a repurchase option such that, upon termination of the employee, director, consultant or other service provider,
as the case may be, whether such termination be with or without cause, the Company or its assignee (to the extent permissible under applicable securities laws) retains the option to repurchase any unvested shares held by such employee, director,
consultant or other service provider at the price such employee, director, consultant or other service provider paid for the shares. 

3.5        Key Man Life Insurance.  The Company shall maintain a “key
person” term life insurance policy, secured from a financially sound and reputable insurer, which names the Company as sole beneficiary, on such executives and on such terms as are reasonably acceptable to the Board. 

3.6        Directors’ & Officers’ Liability.  The Company
shall maintain a policy or policies of directors’ and officers’ liability insurance (“D&O Insurance”) on terms and conditions reasonably acceptable to the Company and the Holders who in the aggregate hold more
than sixty percent (60%) of the Common Stock then issued or issuable upon conversion of the Shares. The Company shall keep such D&O Insurance in place so long as any of the Major Investors’ designees serve on the Board. In addition,
the Company’s Certificate of Incorporation and Bylaws shall provide for (a) elimination of the liability of directors to the maximum extent permitted by law and (b) indemnification of directors for acts on behalf of the Company to the
maximum extent permitted by law. 
 3.7        Board Committees.  The
Audit and Compensation Committees of the Board shall be composed of non-management directors. The Audit Committee shall include at least one Series A Director, the Series C Director and one Series D Director (each, as defined in the Restated
Certificate), and the Compensation Committee shall include at least one Series A Director, the Series B Director, the Series C Director and one Series D Director (as defined in the Restated Certificate). The Compensation Committee shall be
responsible for reviewing and approving all option grants. 
 3.8        Actions
Requiring Board Approval.  So long as shares of Preferred Stock remain outstanding, the Company will not, without the approval of the Board (and without 

 

 21 

 
complying with any other approval required by the Company’s certificate of incorporation, if any): 

(a)        make any loan or advance to, or own any stock or other securities of, any subsidiary
or other corporation, partnership, or other entity unless it is wholly-owned by the Company; 

(b)        make any loan or advance to any person, including any employee or director, except
advances and similar expenditures in the ordinary course of business or under the terms of a employee stock or option plan approved by the Board; 

(c)        guarantee any indebtedness except for trade accounts of the Company or any subsidiary
arising in the ordinary course of business; 
 (d)        make any investment other
than investments pursuant to a Board-approved investment policy, including in prime commercial paper, money market funds, certificates of deposit in any United States bank having a net worth in excess of $100,000,000 or obligations issued or
guaranteed by the United States of America, in each case having a maturity not in excess of two years; 

(e)        incur any aggregate indebtedness in excess of $500,000 that is not already included
in a Board-approved budget, other than trade credit incurred in the ordinary course of business; 

(f)        enter into or be a party to any transaction with any director, officer or employee of
the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such person except compensation paid in the ordinary course of business or transactions resulting in payments to or by the Company in an
amount less than $60,000 per year; 
 (g)        hire, fire or change the compensation
of the executive officers, including approving any equity incentive compensation or any severance or change of control arrangements; 

(h)        change the principal business of the Company, enter new lines of business or exit the
current line of business; or 
 (i)        sell, transfer, license, pledge or encumber
technology or intellectual property, other than licenses granted in the ordinary course of business. 

3.9        Actions Requiring a Waiver of the Preferred.  So long as shares of
Preferred Stock remain outstanding, unless waived by the holders of at least sixty percent (60%) of the then outstanding Preferred Stock, the Company will: 

(a)        maintain its corporate existence and good standing; 

(b)        pay all taxes when due, including withholding taxes, except for such taxes being
contested in good faith by appropriate proceedings; 
  

 22 

 (c)        promptly provide each Major Investor
with written notice of any claim made or threatened in writing by any third party with potential liability in excess of $250,000; and 

(d)        maintain commercially reasonable general liability, casualty and product liability
insurance. 
 3.10        Company Confidential
Information.  Notwithstanding anything to the contrary in this Section 3, no Holder by reason of this Agreement shall have access to any trade secrets or classified information of the Company. Each Holder agrees to hold in
confidence and trust and not to misuse or disclose any confidential information provided pursuant to this Section 3. The Company shall not be required to comply with this Section 3 in respect of any Holder whom the Company reasonably
determines to be a competitor or an officer, employee, director, or greater than ten percent (10%) stockholder of a competitor. Notwithstanding the foregoing, no information which is confidential or proprietary in nature shall be disclosed to
Genentech, Inc. (“Genentech”) pursuant to this Agreement. Any confidential or proprietary information disclosed to Genentech shall be disclosed pursuant to a separate confidential disclosure agreement signed by the Company
and Genentech. 
 3.11        Observer Rights. 

(a)        Until August 10, 2010, provided Essex or its affiliate continues to hold shares
of Preferred Stock, the Company shall allow one individual designated by Essex or its affiliate to attend all meetings of its Board in a nonvoting observer capacity (the “Essex Representative”), and, in connection therewith,
shall give the Essex Representative copies of all notices, minutes, consents and other materials that it provides to its directors at the same time and in the same manner as provided to such directors. The Essex Representative shall agree to hold in
confidence and trust and to act in a fiduciary manner with respect to all such materials and all information it obtains at each such meeting and the Company reserves the right to withhold any materials and information and to exclude the Essex
Representative from any meeting or portion thereof if the Company or the Board believes that such withholding or exclusion is reasonably necessary (i) to preserve the attorney-client privilege, (ii) to protect highly confidential and
proprietary information, (iii) to preserve any fiduciary obligations of the Board, (iv) to prevent any conflict of interest, (v) to protect information regarding potential or actual strategic investments or partnerships with a
commercial entity or (vi) for other similar reasons. The Company shall not be required to comply with the provisions of this Section 3.11(a) if Essex or the Essex Representative becomes a holder of more than five percent (5%) of the
outstanding securities of a competitor of the Company or if the Essex Representative becomes an officer, employee or director of a competitor of the Company. 

(b)        As long as OrbiMed or its affiliate continues to hold at least fifty percent
(50%) of the Series D Preferred Stock issued by the Company to OrbiMed pursuant to that certain Series D Preferred Stock Purchase Agreement, dated as of August 12, 2009, among the Company and the entities and individuals listed on Exhibit
A thereto, as amended, the Company shall allow one individual designated by OrbiMed or its affiliate to attend all meetings of its Board in a nonvoting observer capacity (the “OrbiMed Representative”), and, in connection
therewith, shall give the OrbiMed Representative copies of all notices, minutes, 
  

 23 

 
consents and other materials that it provides to its directors at the same time and in the same manner as provided to such directors. The OrbiMed Representative shall agree to hold in confidence
and trust and to act in a fiduciary manner with respect to all such materials and all information it obtains at each such meeting and the Company reserves the right to withhold any materials and information and to exclude the OrbiMed Representative
from any meeting or portion thereof if the Company or the Board believes that such withholding or exclusion is reasonably necessary (i) to preserve the attorney-client privilege, (ii) to protect highly confidential and proprietary
information, (iii) to preserve any fiduciary obligations of the Board, (iv) to prevent any conflict of interest, (v) to protect information regarding potential or actual strategic investments or partnerships with a commercial entity
or (vi) for other similar reasons. The Company shall not be required to comply with the provisions of this Section 3.11(b) if OrbiMed or the OrbiMed Representative becomes a holder of more than five percent (5%) of the outstanding
securities of a competitor of the Company or if the OrbiMed Representative becomes an officer, employee or director of a competitor of the Company. 

(c)        As long as Highland continues to hold at least fifty percent (50%) of the Series
C Preferred held by Highland at the Initial Closing (as defined in the Purchase Agreement), the Company shall allow one individual designated by Highland to attend all meetings of its Board in a nonvoting observer capacity (the “Highland
Representative”), and, in connection therewith, shall give the Highland Representative copies of all notices, minutes, consents and other materials that it provides to its directors at the same time and in the same manner as provided to
such directors. The Highland Representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all such materials and all information it obtains at each such meeting and the Company reserves the right to
withhold any materials and information and to exclude the Highland Representative from any meeting or portion thereof if the Company or the Board believes that such withholding or exclusion is reasonably necessary (i) to preserve the
attorney-client privilege, (ii) to protect highly confidential and proprietary information, (iii) to preserve any fiduciary obligations of the Board, (iv) to prevent any conflict of interest, (v) to protect information regarding
potential or actual strategic investments or partnerships with a commercial entity or (vi) for other similar reasons. The Company shall not be required to comply with the provisions of this Section 3.11(c) if Highland or the Highland
Representative becomes a holder of more than five percent (5%) of the outstanding securities of a competitor of the Company or if the Highland Representative becomes an officer, employee or director of a competitor of the Company. 

(d)        As long as Sands or its affiliates continues to hold at least fifty percent
(50%) of the Series E Preferred Stock issued by the Company to Sands pursuant to the Purchase Agreement, the Company shall allow one individual designated by Sands or its affiliates to attend all meetings of its Board in a nonvoting observer
capacity (the “Sands Representative”), and, in connection therewith, shall give the Sands Representative copies of all notices, minutes, consents and other materials that it provides to its directors at the same time and in
the same manner as provided to such directors. The Sands Representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all such materials and all information it obtains at each such meeting and the
Company reserves the right to withhold any materials and information and to exclude the Sands Representative from any meeting or portion thereof if the Company or the Board believes that such withholding or exclusion is reasonably necessary
(i) to preserve the attorney-client privilege, (ii) to protect 
  

 24 

 
highly confidential and proprietary information, (iii) to preserve any fiduciary obligations of the Board, (iv) to prevent any conflict of interest, (v) to protect information
regarding potential or actual strategic investments or partnerships with a commercial entity or (vi) for other similar reasons. The Company shall not be required to comply with the provisions of this Section 3.11(d) if Sands or the Sands
Representative becomes a holder of more than five percent (5%) of the outstanding securities of a competitor of the Company or if the Sands Representative becomes an officer, employee or director of a competitor of the Company. 

3.12        Debt Offerings.  If the Company elects to raise capital through a
debt offering, including the issuance of bonds or establishment of a loan, the Company shall provide written notice to Highland of the Company’s decision to raise capital in this manner and Highland shall have thirty (30) days from
delivery of such notice to elect to provide financing for the Company; provided, however, that the financing shall be on terms acceptable to the Company in the Company’s sole discretion. 

3.13        Termination of Covenants.  The covenants set forth in this
Section 3 shall terminate and be of no further force or effect after the earlier of (i) the date on which the Company is required to file reports with the Commission pursuant to Section 13 or 15(d) of the Exchange Act and
(ii) the occurrence of any of the events specified in Section 2.3 hereof; provided, that the covenants set forth in Section 3.6 shall not terminate so long as any Major Investor’s designee serves on the Board. 

4.    Acknowledgement.  The Company hereby acknowledges that one (1) or more of the directors
nominated to serve on the Board by the Investors (each, a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their
affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (that is, its obligations to any such Fund Director are primary and any obligation of the Fund
Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund
Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the Restated Certificate or
Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and (c) that it irrevocably waives, relinquishes and releases the Fund
Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any
such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such
advancement or payment to all of the rights of recovery of such Fund Director against the Company. 

5.    Miscellaneous. 
  

 25 

 5.1        Governing Law.  This
Agreement shall be governed in all respects by the laws of the State of California without regard to choice of laws or conflict of laws provisions thereof. 

5.2        Successors and Assigns.  Except as otherwise provided herein, the
provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. Nothing in this Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided by this Agreement. 

5.3        Entire Agreement.  This Agreement and the other documents delivered
pursuant hereto constitute the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof. Subject to the provisions of Section 5.10 below, neither this Agreement nor any term hereof may be
amended, waived, discharged or terminated other than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought, unless otherwise provided. 

5.4        Notices.  All notices and other communications required or
permitted hereunder shall be in writing and shall be mailed by registered mail, certified mail (return receipt requested) or by internationally recognized express courier (e.g., Federal Express), postage prepaid, or sent by fax or otherwise
delivered by hand or by messenger addressed: 
 (a)        If to an Investor, at the
Investor’s address or fax number set forth beneath such Investor’s signature hereto, or at such other address as such Investor shall have furnished to the Company; 

(b)        If to the Company, one copy should be sent to its address or fax number of record and
addressed to the attention of the President, or at such other address or fax number as the Company shall have furnished to the parties hereto, with copies to Alan C. Mendelson and Greg Chin, Latham & Watkins LLP, 140 Scott Drive, Menlo
Park, California 94025, (fax) 650-463-2600; and 
 (c)        Each such notice shall
for all purposes of this Agreement be treated as effective or having been given on the earliest to occur of the following: 

(i)        The date of personal delivery or delivery by messenger; 

(ii)        One (1) business day after transmission by fax, with confirmation of
transmission; 
 (iii)        One (1) business day after deposit with an
internationally recognized express courier for United States deliveries, or three (3) business days after such deposit for deliveries outside of the United States; or 
  

 26 

 (iv)        Three (3) business days after
deposit in a regularly maintained receptacle for the deposit of the United States mail be registered or certified mail (return receipt requested) for United States deliveries. 

5.5        Delays or Omissions.  No delay or omission to exercise any right,
power, or remedy accruing to any Holder upon any breach or default of the Company under this Agreement shall impair any such right, power, or remedy of such party, nor shall it be construed to be a waiver of any such breach or default, or an
acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit,
consent, or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective
only to the extent specifically set forth in such writing or as provided in this Agreement. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

5.6        Dispute Resolution Fees.  If any action at law or in equity is
necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs, and disbursements in addition to any other relief to which such party may be entitled. 

5.7        Counterparts.  This Agreement may be executed in any number of
counterparts and signatures may be delivered by facsimile, each of which may be executed by less than all parties, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall
constitute one instrument. 
 5.8        Severability.  If any
provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable, or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this
Agreement and the balance of this Agreement shall be enforceable in accordance with its terms. 

5.9        Titles and Subtitles.  The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

5.10        Amendment and Waiver.  Any provision of this Agreement may be
amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and a Holder or Holders holding, in the aggregate, more than sixty percent (60%) of the
outstanding shares of Common Stock issued or issuable pursuant to conversion of the Shares. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each Holder and the Company; provided, however, that any amendment
that would materially and adversely affect the rights of, or impose additional material obligations on, any Holder or groups of Holders in a manner different than the other Holders shall not be effective against such affected Holder without the
written consent of such Holder. In addition, except as provided in Section 1.14 above, the Company may waive 
  

 27 

 
performance of any obligation owing to it, as to some or all of the Holders, or agree to accept alternatives to such performance, without obtaining the consent of any Holder. Notwithstanding
anything to the contrary herein, if the Company shall issue additional shares of Series E Preferred pursuant to the Purchase Agreement, any purchaser of such shares of Series E Preferred may become a party to this Agreement by delivering an executed
counterpart signature page to the Company and such purchaser shall be deemed an “Investor” hereunder, all without the requirement of any consent from any party hereunder or amendment or waiver hereof. 

5.11        Effect of Amendment or Waiver.  The Holders and their successors
and assigns acknowledge that by the operation of Section 5.10 hereof Holders holding more than sixty percent (60%) of the outstanding shares of Common Stock issued or issuable pursuant to conversion of the Shares, acting in conjunction
with the Company, will have the right and power to diminish or eliminate any or all rights pursuant to this Agreement. 

5.12        Termination of Prior Agreement.  The Prior Agreement is hereby
amended and restated in full to read as set forth herein. 

5.13        Waiver.  The Investors who were party to the Prior Agreement and
who were “Major Investors” as defined in the Prior Agreement hereby waive any and all right of first refusal and notice requirements set forth in Section 2.1 of the Prior Agreement with respect to the issuance of the Series E
Preferred pursuant to the Purchase Agreement. The Investors who were party to the Prior Agreement also hereby consent to the registration rights granted herein as required by Section 1.12 of the Prior Agreement. 

5.14        Rights of Investors.  Each party to this Agreement shall have the
absolute right to exercise or refrain from exercising any right or rights that such party may have by reason of this Agreement, including, without limitation, the right to consent to the waiver or modification of any obligation under this Agreement,
and such party shall not incur any liability to any other party or other holder of any securities of the Company as a result of exercising or refraining from exercising any such right or rights. 

5.15        Aggregation of Stock.  All shares of Preferred Stock and Common
Stock of the Company held or acquired by affiliated entities or persons (including those held by Affiliated Entities) shall be aggregated for the purpose of determining the availability of any rights under this Agreement. 

5.16        Specific Performance.  The rights of the parties under this
Agreement are unique and, accordingly, the parties shall, in addition to such other remedies as may be available to any of them at law or in equity, have the right to enforce their rights hereunder by actions for specific performance to the extent
permitted by law. 
 5.17        Jurisdiction and Venue; Waiver of Jury
Trial.  Any action, suit or proceeding arising out of or relating to this Agreement shall be brought in the state courts of the State of California located in Santa Clara County, or, if it has or can acquire jurisdiction, any Federal
court located in such State and County, and EACH OF THE PARTIES HERETO, AFTER CONSULTING WITH OR HAVING HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL, HEREBY KNOWINGLY, VOLUNTARILY, INTENTIONALLY AND 

 

 28 

 
IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS AND WAIVES TRIAL BY JURY, IN EACH CASE IN CONNECTION WITH ANY ACTION, SUIT OR PROCEEDING ARISING OUT OF OR RELATING TO THIS
AGREEMENT. Each of the parties hereto hereby irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby in the
courts of the State of California or the United States of America, in each case located in Santa Clara County, and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought
in any such court has been brought in an inconvenient forum. 
 [THIS SPACE LEFT BLANK INTENTIONALLY] 

 

 29 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first
above written. 
  

			
	COMPLETE GENOMICS, INC.
		
	By:	 	        /s/ Ajay Bansal
		 	Ajay Bansal
		 	Chief Financial Officer
		
		 	Company Address:
		
		 	2071 Stierlin Court
Mountain View, CA 94043

SIGNATURE PAGE TO THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

							
	Investors:
	
	ESSEX WOODLANDS HEALTH VENTURES FUND VIII, L.P.
		
	By:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.
Its General Partner
			
		 	By:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, LLC
Its General Partner
				
		 		 	By:	 	        /s/ Jeff Himawan
		 		 	Name:	 	Jeff Himawan
		 		 	Title:	 	Manager
		
	Address:	 	335 Bryant Street
		
		 	Palo Alto, CA 94301
		 	Attn: Jeff Himawan
		
	Fax No:	 	(650) 327-9755
	
	ESSEX WOODLANDS HEALTH VENTURES FUND VIII-A, L.P.
		
	By:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.
Its General Partner
			
		 	By:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, LLC
Its General Partner
				
		 		 	By:	 	        /s/ Jeff Himawan
		 		 	Name:	 	 Jeff Himawan

		 		 	Title:	 	 Manager

		
	Address:	 	335 Bryant Street
		 	Palo Alto, CA 94301
		 	Attn: Jeff Himawan
	Fax No:	 	(650) 327-9755

SIGNATURE PAGE TO THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

							
	Investors:
	
	ESSEX WOODLANDS HEALTH VENTURES FUND VIII-B, L.P.
		
	 By:
	 	ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.
Its General Partner
			
		 	By:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, LLC
Its General Partner
				
		 		 	By:	 	        /s/ Jeff Himawan
		 		 	Name:	 	Jeff Himawan
		 		 	Title:	 	Manager
		
	Address:	 	335 Bryant Street
		 	Palo Alto, CA 94301
		 	Attn: Jeff Himawan
	Fax No:	 	(650) 327-9755

SIGNATURE PAGE TO THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

			
	Investors:
	
	ORBIMED ASSOCIATES III, LP
		
	By:	 	        /s/ Carl Gordon
		 	Carl Gordon
		 	General Partner
	
	Address: 767 Third Avenue,
30th Floor
New York, NY 10017
	
	CADUCEUS PRIVATE INVESTMENTS III, LP
		
	By:	 	        /s/ Carl Gordon
		 	Carl Gordon
		 	General Partner
	
	Address: 767 Third Avenue,
30th Floor
New York, NY
10017

 SIGNATURE PAGE TO THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

			
	Investors:
	
	HIGHLAND CRUSADER OFFSHORE PARTNERS, L.P.
	By:	 	Highland Crusader Fund GP, L.P.
	Its:	 	General Partner
	By:	 	Highland Crusader GP, LLC.
	By:	 	Highland Capital Management, L.P.
	Its:	 	Sole Member
	By:	 	Strand Advisors, Inc.
	Its:	 	General Partner

			
	
	/s/ Michael S. Colvin
	Name:	 	Michael S. Colvin
	Title:	 	Secretary

  

			
	
	HIGHLAND CREDIT OPPORTUNITIES CDO L.P.
	By:	 	Highland Credit Opportunities CDO GP, L.P.
	Its:	 	General Partner
	By:	 	Highland Credit Opportunities CDO GP, LLC
	Its:	 	General Partner
	By:	 	Highland Capital Management, L.P.
	Its:	 	Sole Member
	By:	 	Strand Advisors, Inc.
	Its:	 	General Partner

			
	
	/s/ Michael S. Colvin
	Name:	 	Michael S. Colvin
	Title:	 	Secretary

 SIGNATURE PAGE TO THE FOURTH
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

			
	Investors:
	
	OVP Venture Partners VI, L.P.
	By:	 	OVMC VI, LLC, as General Partner
		
	By:	 	        /s/ Charles Waite
		 	Managing Member or Attorney In Fact

			
		
	Address:	 	1010 Market Street
		 	Kirkland WA 98033

  

			
	OVP VI Entrepreneurs Fund, L.P.
	By:	 	OVMC VI, LLC, as General Partner
		
	By:	 	        /s/ Charles Waite
		 	Managing Member or Attorney In Fact

			
		
	Address:	 	1010 Market Street
		 	Kirkland WA 98033

 SIGNATURE PAGE TO
THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

			
	Investors:
	
	Enterprise Partners VI, LP
	By:      	 	Enterprise Management Partners VI, LLC as General Partner
	
	/s/ Andrew E. Senyei
	By:	 	Andrew E. Senyei
		 	Managing Director

			
		
	Address:	 	2223 Avenida de la Playa
		 	Suite 300
		 	La Jolla CA 92037

  

			
	Enterprise Partners V, LP
	By:      	 	Enterprise Management Partners VI, LLC as General Partner
	
	/s/ Andrew E. Senyei
	By:	 	Andrew E. Senyei
		 	Managing Director

			
		
	Address:	 	2223 Avenida de la Playa
		 	Suite 300
		 	La Jolla CA 92037

  

	
	Enterprise Partners Management, LLC
	
	/s/ Andrew E. Senyei
	Andrew E. Senyei
	As sole Director of Andrew E. Senyei, Inc.
	Manager of Enterprise Partners Management, LLC
	
	Address:
	2223 Avenida de la Playa
	La Jolla CA 92037

 SIGNATURE PAGE TO
THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

			
	Investors:
	
	Prospect Venture Partners III, L.P.
	By:      	 	Prospect Management Co. III, L.L.C.
	Its:	 	General Partner
	
	/s/ Alex Barkas
	Name:	 	
	Title:	 	Managing Director
	
	Address:

 SIGNATURE PAGE TO
THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

			
	Investors:
	
	SVC –CG, LLC
		
	By:	 	        /s/ Charles Preston
	Name:	 	Charles Preston
	Title:	 	
	
	Address:

 SIGNATURE PAGE TO
THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

			
	Investors:
	
	The Mendelson Family Trust
	
	/s/ Alan C. Mendelson
	By:	 	Alan C. Mendelson
	Title:	 	Trustee

  

			
	VP Company Investments 2004, LLC
	
	/s/ Alan C. Mendelson
	By:	 	Alan Mendelson
	Title:	 	Managing Member
	Address:	 	555 West Fifth Street
		 	Suite 80
		 	Los Angeles, CA 90013

  

			
	VP Company Investments 2008, LLC
	
	/s/ Alan C. Mendelson
	By:	 	Alan Mendelson
	Title:	 	Managing Member
	Address:	 	555 West Fifth Street
		 	Suite 80
		 	Los Angeles, CA 90013

 SIGNATURE PAGE
TO THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

	
	Investors:
	
	/s/ C. Thomas Caskey
	C. Thomas Caskey, M.D.

 SIGNATURE
PAGE TO THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

	
	Founders:
	
	 THE CURSON FAMILY LIVING TRUST

DATED JULY 30, 2001

	
	        /s/ Robert John Curson
	Robert John Curson, Trustee
	
	DRMANAC FAMILY TRUST DATED JUNE 21, 2000
	
	        /s/ Radoje Drmanac
	Radoje Drmanac, Trustee
	
	CLIFFORD A. REID LIVING TRUST, DATED SEPTEMBER 3, 1997
	
	        /s/ Clifford A. Reid            

	Clifford A. Reid, Trustee

  

SIGNATURE PAGE TO THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

	
	Founders:
	
	ROBERT JOHN CURSON
	
	        /s/ Robert John Curson
	
	RADOJE DRMANAC
	
	        /s/ Radoje Drmanac
	
	CLIFFORD A. REID
	
	        /s/ Clifford A. Reid

 
  
  

SIGNATURE PAGE TO THE FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 EXHIBIT A 

SCHEDULE OF INVESTORS 

Essex Woodlands Health Ventures Fund VIII, L.P. 

Essex Woodlands Health Ventures Fund VIII -A, L.P. 

Essex Woodlands Health Ventures Fund VIII-B, L.P. 

OrbiMed Associates III, LP 
 Caduceus Private
Investments III, LP 
 Highland Crusader Offshore Partners, L.P. 

Highland Credit Opportunities CDO, L.P. 
 OVP
Venture Partners VI, L.P. 
 OVP VI Entrepreneurs Fund L.P. 

Enterprise Partners VI, LP 
 Enterprise Partners
V, L.P. 
 Aquilo Partners, L.P. 

Prospect Venture Partners III, L.P. 
 The
Mendelson Family Trust 
 VP Company Investments 2004, LLC 

VP Company Investments 2008, LLC 
 Gold Hill
Venture Lending 03, LP 
 Genentech, Inc. 

C. Thomas Caskey, M.D. 
 Enterprise Partners
Management, LLC 
 SCV-CG, LLC 

 EXHIBIT B 

SCHEDULE OF FOUNDERS 

The Curson Family Living Trust Dated July 30, 2001 

Drmanac Family Trust Dated June 21, 2000 

Clifford A. Reid Living Trust, Dated September 3, 1997 

Robert John Curson 
 Radoje Drmanac 

Clifford A. ReidManufacturing Service Agreement

 Exhibit 10.26 

`MANUFACTURING SERVICES AGREEMENT 

THIS AGREEMENT (the “Agreement”) is effective as of March 22, 2010 (the “Effective Date”), by and between SYMMETRICOM,
INC., a Delaware corporation having a principal place of business at 2300 Orchard Parkway, San Jose, CA 95131, on behalf of itself and its affiliates or subsidiaries (collectively “CUSTOMER”) and SANMINA-SCI CORPORATION,
a Delaware corporation having its principal place of business at 2700 North First Street, San Jose, California 95134, on behalf of itself and its affiliates or subsidiaries (“SANMINA-SCI”). CUSTOMER and SANMINA-SCI are sometimes referred
to herein as a “Party” and the “Parties.” 
 WHEREAS, Customer is a leading developer and supplier of products and services
for the generation and synchronization of precise timing for the communications, government and other markets; 
 WHEREAS, SANMINA-SCI provides
contract manufacturing services from its facilities located worldwide; 
 WHEREAS, Customer may, among other things desire to have Sanmina-SCI
procure components, parts, and raw material and assemble and manufacture for and ship products to Customer. 
 NOW, THEREFORE, in consideration
of the mutual promises and conditions set forth herein, and intending to be legally bound, the Parties agree as follows: 
  

	1.	SCOPE AND TERM 

 1.1 This
Agreement sets forth the terms under which Customer may, among other things, have SANMINA-SCI procure components, parts, and raw material (collectively “Components”) and manufacture, assemble, test, inspect, and configure these parts and
Components into finished goods (“Products”) in accordance with Customer’s specifications (“Specifications”). 
 1.2 The
initial term of this Agreement shall commence on the Effective Date and shall continue through the first anniversary of the Effective Date unless sooner terminated by mutual agreement or in accordance with this Agreement. Upon the expiry of the
initial term, this Agreement shall continue from year to year until one Party terminates the Agreement in accordance with section 10 of this agreement. 
  

	2.	PRICING 

 2.1
Pricing. During the term, SANMINA-SCI shall manufacture and sell to CUSTOMER the Products specified by the Customer, as amended from time to time (at the prices set forth in Exhibit A (the “Prices”). Prices (a) are in U.S.
Dollars, (b) include SANMINA-SCI standard packaging, (c) exclude the items set forth in Section 2.2, and (d) are based on (i) the configuration set forth in the Specifications provided to SANMINA-SCI on which
SANMINA-SCI’s quotation was based and (ii) the projected volumes, minimum run rates and other assumptions mutually agreed upon by the parties. The Prices shall remain fixed and reviewed annually subject to SANMINA-SCI’s right to
propose price changes (x) to account for any material variations on the market prices of components, parts and raw material (collectively “Components”), including any such variations resulting from allocations or shortages as ;
(y) to account for any changes in the exchange rate between the currency in which the pricing is calculated and the currency in which SANMINA-SCI pays for its labor, overhead and Components or (z) the price adjustments as set forth in
Section 2.3. Any pricing SANMINA-SCI gives to Customer shall specify line item pricing, time and rate and any price adjustments shall be mutually agreed to between the Parties. 

 

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 2.2 Exclusions from Price. Prices specifically exclude (a) export licensing of
the Product and payment of broker’s fees, duties, tariffs and other similar charges; (b) taxes or charges (other than those based on net income of SANMINA-SCI) imposed by any taxing authority upon the manufacture, sale, Shipment storage,
“value add” or use of the Product; and (c) setup, tooling, or non-recurring engineering activities (collectively “NRE Charges”). 

2.3 Other Price Adjustments: 

(a) CUSTOMER acknowledges that the Prices set forth in Exhibit A are based on the forecasted volumes provided by CUSTOMER to SANMINA-SCI.
In the event CUSTOMER does not purchase Product in sufficient volumes consistent with the quoted prices, the Parties will review the prices and volumes quarterly and any price adjustments shall be mutually agreed to between the Parties during the
quarterly pricing review. 
 (b) CUSTOMER acknowledges that the Prices are based on the Specifications and the assumptions set
forth in SANMINA-SCI’s quotation and in Exhibit A. In the event SANMINA-SCI experiences an increase or decrease in cost as a result of changes in the pricing assumptions or the Specifications, SANMINA-SCI shall propose such cost changes during
the quarterly cost review cycle and any changes in pricing must be mutually agreed upon by both parties. 
  

	3.	PAYMENT TERMS/SETOFFS/CREDIT LIMIT 

3.1 Payment Terms. Payment terms for shipments originating from [***] are [***]. Payment terms for shipments originating from [***] shall
be (a) [***], and (b) [***]. Any pricing or quantity discrepancies must be brought to SANMINA-SCI’s attention within [***] after receiving an invoice. Invoice to be issued only when title transfers. Unless otherwise stated, payment
shall be made in U.S. Dollars. 
 3.2 Setoffs. Each Party shall be entitled at all times to set-off any amount owing from
the other Party to such Party against any amount payable to the other Party under this Agreement from such Party, arising out of this or any other transaction under this Agreement. For purposes hereof, (i) the term “Party” shall
include the Parties to this transaction and each Party’s Affiliates and (ii) a Party’s “Affiliate” shall mean any entity that, directly or through one or more intermediaries, controls, is controlled by or is under common
control by such Party, including but not limited to a Party’s subsidiaries. 
 3.3 Credit Limit. SANMINA-SCI’s
Credit Department shall provide CUSTOMER with an initial credit limit, which shall be reviewed (and, if necessary, adjusted) from time to time. In the event CUSTOMER’s payments are in arrears, SANMINA-SCI shall have the right to reduce the
credit limit upon thirty (30) days’ prior written notice to CUSTOMER. In the event CUSTOMER has any outstanding invoice, which are not subject to good faith dispute by Customer and which are more than thirty (30) days past due,
SANMINA-SCI shall have the right to stop shipments of Product to CUSTOMER until CUSTOMER makes a sufficient payment to bring its account within the credit limit provided. 

 

	4.	PURCHASE ORDERS/FORECAST/RESCHEDULE 

The following process under this Section 4 shall apply until or unless a VMI agreement has been executed by the Parties, in which event the VMI
agreement will be made part of this Agreement and attached to this Agreement as Exhibit D and will control with respect to this Section. 
  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 4.1 Purchase Orders. 

(a) CUSTOMER will issue to SANMINA-SCI specific Orders for Product covered by this Agreement. Each Order shall be in the form of a
written or electronic communication and shall contain the following information: (i) the part number of the Product; (ii) the quantity of the Product; (iii) the delivery date or shipping schedule; (iv) the location to which the
Product is to be shipped; and (v) transportation instructions. Each Order shall contain a number for billing purposes, and may include other instructions and terms (provided that such terms do not conflict with this Agreement) as may be
appropriate under the circumstances. 
 (b) All Orders shall be confirmed by SANMINA-SCI within five (5) business days of
receipt If SANMINA-SCI does not accept or reject the Order within the five day period, the Order shall be deemed rejected by SANMINA-SCI. In the event SANMINA-SCI is unable to meet the delivery schedule set forth in a proposed Order, or finds the
schedule or if the Order does not conform to this Agreement, the Parties shall negotiate in good faith to resolve the disputed matter(s). 

4.2 Forecast; Minimum Buys; Excess and Obsolete Inventory. 

(a) Initial Forecast. [***] 

(b) Subsequent Forecasts. On the first business day of each calendar month after the initial Order and Forecast, the first
Forecast month shall automatically become part of the Order, a new Forecast month shall be added, and a new firm Order issued, so that a rolling Order of [***] is always maintained. 

(c) MRP Process. 

(1) SANMINA-SCI shall take the Order and Forecast and generate a Master Production Schedule (“MPS”) for a [***] in accordance
with the process described in this Section. The MPS shall define the master plan on which SANMINA-SCI shall base its procurement, internal capacity projections and commitments. SANMINA-SCI shall use CUSTOMER’s Order to generate the first [***]
of the MPS and shall use CUSTOMER’s Forecast to generate the subsequent [***] of the MPS. 
 (2) SANMINA-SCI shall process
the MPS through industry-standard software (the “MRP Software”) that will break down CUSTOMER’s Product requirements into Component requirements. When no Product testing (in-circuit or functional testing) is required by CUSTOMER,
SANMINA-SCI will use commercially reasonable efforts to schedule delivery of all Components to SANMINA-SCI eleven working days before the Products are scheduled to ship to CUSTOMER; in the event Product testing is required, SANMINA-SCI will use
commercially reasonable efforts to schedule delivery of all Components to SANMINA-SCI [***] before the Products are scheduled to ship to CUSTOMER. 

(3) SANMINA-SCI will release (launch) purchase orders to Vendors (including other SANMINA-SCI facilities) prior to the anticipated date
that the Components are needed at SANMINA-SCI. The date on which these orders are launched will depend on the lead time determined between the Vendor and SANMINA-SCI and SANMINA-SCI’s manufacturing or materials planning systems. 

(4) A list of all Components with lead times greater than [***] (or the Order period, if the Order period is less [***]) (“Long
Lead-time Components”) shall be provided to Customer and identified in Exhibit B to this Agreement. SANMINA-SCI shall update the list of Long Lead-time Components [***] and present an updated list of Long Lead-time Components to

  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 
CUSTOMER at the time SANMINA-SCI presents the CUSTOMER with the E&O List described in Section 4.2(e). Each revised Long Lead-time Item list shall be deemed an amendment to Exhibit B,
whether or not it has been formally designated as such. In the event SANMINA-SCI fails to present an updated list of Long Lead-time Components, (i) the Parties shall continue to rely on the preceding list (as updated in writing by the Parties)
and (ii) CUSTOMER will accept responsibility for Long Lead-time Components ordered outside the lead-times set forth in the list provided that SANMINA-SCI can demonstrate to CUSTOMER’s reasonable satisfaction that such Components were
ordered in accordance with the then-current Vendor lead-times and CUSTOMER Forecast. (CUSTOMER acknowledges that lead-times constantly change and that SANMINA-SCI might not always be able to present CUSTOMER with a current Long Leadtime Component
List). 
 (5) CUSTOMER acknowledges that SANMINA-SCI will order Components in quantities sufficient to support CUSTOMER’s
Forecast. [In determining the quantity of Components to order, SANMINA-SCI divides the Components into three classes, “Class A,” “Class B” and “Class C.” Class A Components are comprised of [***]. Class C
Components are comprised of [***]. Class B Components are comprised of [***]. [***]. A summary of SANMINA-SCI’s purchase commitments is set forth in the table below. 

 

							
	 Part Class
	  	[***]	 	[***]	 	[***]
	 A
	  	[***]	 	[***]	 	[***]
	 B
	  	[***]	 	[***]	 	[***]
	 C
	  	[***]	 	[***]	 	[***]

 (6) CUSTOMER acknowledges that
SANMINA-SCI will be required to order Components in accordance with the various minimum buy quantities, tape and reel quantities, and multiples of packaging quantities required by the Vendor. 

(d) Reschedule. CUSTOMER may, at any time, reschedule all or part of a scheduled delivery of an Order prior to shipment upon
written notice to Sanmina-SCI, with reschedule not to exceed [***] in accordance with the table below. 
 At the end of this [***] period,
CUSTOMER shall either accept delivery of rescheduled finished units and/or pay SANMINA-SCI’s Component Cost associated with rescheduled units not yet built. 
  

			
	 Days Before P.O. Delivery Date
	  	 Percentage Reschedule Allowance

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 SANMINA-SCI shall use reasonable commercial efforts
to accommodate any upside schedule changes beyond the firm Order periods. 
  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 (e) Excess and Obsolete Inventory. 

For the purpose of this Agreement, 

a. “Delivered Cost” shall mean SANMINA-SCI’s quoted cost of Components as stated on the bill of materials, plus a
materials margin equal to [***] percent [***]. 
 b. “Excess Inventory” means the Inventory that SANMINA-SCI
has on hand, which has been ordered, manufactured, or acquired (in accordance with the requirements of this Section 4), based on CUSTOMER’s then-current Forecast or Orders, greater than the Customer’s next [***] demand, which is
subject to the reconciliation process defined in Section 4.2 (g) and the ABC Stratification process as defined Section 4.2 (c) (5). 

c. “Obsolete Inventory” means: the quantity of Inventory that SANMINA-SCI has on hand, which has been ordered,
manufactured, or acquired (in accordance with the requirements of this Section 4) based on CUSTOMER’s then-current Forecast or Orders, but which SANMINA-SCI no longer requires as a result of (i) CUSTOMER’s announcement or
notification that the Product into which such Inventory is incorporated has reached its end of life (“EOL”), (ii) a change in the specification the Product into which the Inventory is incorporated as a result of an Engineering
Change Notice or otherwise; or (iii) Section 4.2(e)(vii) below. 
 d. Disposition Process: Within [***] after
the end of the second month of calendar quarter, SANMINA-SCI shall advise CUSTOMER in writing of any Excess or Obsolete Inventory in its inventory and their Delivered Cost (the “E&O List”). Sanmina’s E&O list will contain only
inventory items that make up [***] of excess and Obsolescence. Within [***] of receiving SANMINA-SCI’s E&O List, CUSTOMER shall advise SANMINA-SCI of any Component on the E&O List that it believes is not excess or obsolete. Within [***]
after receiving SANMINA-SCI’s E&O List, SANMINA-SCI and CUSTOMER shall finalize the E&O List, and (1) CUSTOMER shall issue to SANMINA-SCI an Order for all mutually agreed upon Excess Inventory on the E&O List, or (2) [***]. If
option 1:CUSTOMER shall pay SANMINA-SCI its Delivered Cost for Components on the E&O List within [***] of the date of invoice. In the event the Parties cannot agree as to the Components on the E&O List, [***]. For the purpose of this
Section, the phrase “obsolete Component” shall mean any Component which is not currently used to manufacture CUSTOMER’s Product (whether as a result of an ECO or otherwise), and the term “excess Component” shall mean any
Component which is not required to meet CUSTOMER’s Order or CUSTOMER’s Forecast to which such Component was initially ordered. CUSTOMER shall not have the right to delay payment for excess Components by increasing or pushing out its
Forecast. 
 (f) Customer Component Liability. Customer’s Component liability for any termination without Cause
shall be as set forth in Section 10 below. CUSTOMER acknowledges that it shall be financially liable for all Components ordered in accordance with this Section. Specifically, CUSTOMER’s Component Liability shall be equal to
SANMINA-SCI’s Delivered Cost of all Components ordered in support of any Order or Forecast, including any excess Components resulting from any minimum buy quantities, tape and reel quantities, and multiples of packaging quantities required by
the Vendor less the actual cost (per the bill of materials) of those Components which are returnable to Vendor (less any cancellation or restocking charges). At CUSTOMER’s request, SANMINA-SCI shall use commercially reasonable efforts to
minimize CUSTOMER’s Component Liability by attempting to return Components to the Vendor 
 (g) Supplier Managed
Inventory Program. CUSTOMER acknowledges that the concept of “purchase commitments to a Vendor” (as used in Section 4.2(a) and elsewhere in this Agreement) includes not only SANMINA-SCI purchase orders issued to Vendors,
but also forecasts (which are based on CUSTOMER’s Forecasts) provided to Vendors in accordance with SANMINA-SCI’s Supplier Managed Inventory Program (“SMI Program”). Under the SMI

  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 
Program, SANMINA-SCI provides Vendors with forecasts of anticipated Component requirements, and the Vendor is obligated to supply SANMINA-SCI with all forecasted Components, but SANMINA-SCI does
not issue Vendor a purchase order until the Component is actually required by SANMINA-SCI for production. However, under the SMI Program, SANMINA-SCI is obligated to either consume a sufficient level of the forecasted Components or pay the
Vendor for a certain level of unused Components. For the purpose of this Agreement, CUSTOMER’s Component Liability (pursuant to 4.2(f) above) shall include the cost of any Components actually ordered from the Vendors based
on CUSTOMER’s Forecast and in accordance with the terms of this Agreement. 
  

	5.	DELIVERY ACCEPTANCE; DELAYS 

5.1 Delivery. , all product shipments originating from [***] (including shipments made in accordance with Section 7
“Warranty”) shall be [***]. All product shipments originating from [***] will be (a) [***], and (b) [***].. [***]. . SANMINA-SCI shall mark, pack, package, crate, transport, ship and store Product to ensure (a) delivery of
the Product to its ultimate destination in safe condition, (b) compliance with all requirements of the carrier and destination authorities, and (c) compliance with any special instructions of CUSTOMER. SANMINA-SCI shall notify CUSTOMER of
any anticipated delays. 
 5.2 Acceptance. Customer shall have) [***] from date of receipt of the Product to inspect and
to accept the Products (“Acceptance Period”) In the event Customer rejects the Product as defective, Customer shall have the option of returning the Product [***] to its manufacturing facility for repair, or request an advance replacement
of the Product. In the event Customer requests an advance replacement of the Product(s), Sanmina-SCI shall quickly provide replacement Product to Customer within [***] of Customer’s request, excluding transit time contingent upon Sanmina-SCI
having replacement Product in finished Product inventory. [***]. Notwithstanding anything to the contrary, Product shall be deemed accepted if not rejected within the Acceptance Period. Once a Product is accepted, all Product returns shall be
handled in accordance with Section 7 Warranty. Prior to returning any rejected Product, CUSTOMER shall obtain an Authorized Return Material (“RMA”) number from SANMINA-SCI, and shall return such Product in accordance with
SANMINA-SCI’s instructions; CUSTOMER shall specify the reason for such rejection in all RMA’s. In the event a Product is rejected, SANMINA-SCI shall have a reasonable opportunity to cure any defect which led to such rejection. 

 

	6.	CHANGES 

 6.1
General. CUSTOMER may upon sufficient notice make changes within the general scope of this Agreement. Such changes may include, but are not limited to changes in (1) drawings, plans, designs, procedures, Specifications, test
specifications or bill of material (“BOM”), (2) methods of packaging and shipment, (3) quantities of Product to be furnished, (4) delivery schedule, or (5) Customer-Furnished Items. All changes other than changes in
quantity of Products to be furnished shall be requested pursuant to an Engineering Change Notice (“ECN”) and finalized in an Engineering Change Order (“ECO”). If any such change causes either an increase or decrease in
SANMINA-SCI’s cost or the time required for performance of any part of the work under this Agreement (whether changed or not changed by any ECO) the Prices and/or delivery schedules shall be mutually agreed upon and adjusted in a manner which
would adequately compensate the Parties for such change. 
 6.2 ECN’s. SANMINA-SCI will respond to two (2) ECN
request per month per product family type without a non-recurring administrative fee; responses to additional ECN’s will incur an administrative fee mutually agreed to between both Parties. Within five (5) business days after an ECN is
received, SANMINA-SCI shall advise CUSTOMER in writing (a) of any 
  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 
change in Prices or delivery schedules resulting from the ECN and (b) the Delivered Cost of any Finished Product, Work-in-Process or Component rendered excess or obsolete as a result of the
ECN (collectively the “ECN Charge”). Unless otherwise stated, ECN Charges are valid from thirty (30) days from the date of the ECN Charge. 

6.3 ECO’s. In the event CUSTOMER desires to proceed with the change after receiving the ECN Charge pursuant to
Section 6.2, CUSTOMER shall advise SANMINA-SCI in writing and shall pay the portion of the ECN Charge set forth in Section 6.2(b) thirty (30) days from date of receipt of invoice. In the event CUSTOMER does not desire to proceed with
the Change after receiving the ECN Charge, it shall so notify SANMINA-SCI. In the event SANMINA-SCI does not receive written confirmation of CUSTOMER’s desire to proceed with the change within thirty (30) days after SANMINA-SCI provides
CUSTOMER with the ECN Charge, the ECN shall be deemed cancelled. 
  

	7.	WARRANTY 

 7.1
SANMINA-SCI Warranty. SANMINA-SCI warrants that, for a period of [***], the Product will be free from defects in workmanship and shall strictly conform to the manufacturing requirements contained in Customer’s Specifications, including
but not limited to industry standard IPC-A-600 or IPC-A-610, Class II. SANMINA-SCI shall, at its option and at its expense (and as CUSTOMER’s sole and exclusive remedy for breach of any warranty), [***]. In addition, SANMINA-SCI will pass on to
CUSTOMER all Vendors’ (and manufacturers’) Component warranties to the extent that they are transferable, as well as manage such warranties, but will not independently warrant any Components. All warranty obligations will cease upon the
earlier of the expiration of the warranty period set forth above or the return (at CUSTOMER’s request) of any test equipment or test fixtures. ALL CLAIMS FOR BREACH OF WARRANTY MUST BE RECEIVED BY SANMINA-SCI NO LATER THAN [***] AFTER THE
EXPIRATION OF THE WARRANTY PERIOD. 
 7.2 RMA Process. SANMINA-SCI shall concur in advance on all Products to be returned
for repair or rework. CUSTOMER shall obtain a RMA number from SANMINA-SCI prior to return shipment. All returns shall state the specific reason for such return, and will be processed in accordance with SANMINA-SCI’s RMA process. [***]. Any
repaired or replaced Product shall be warranted as set forth in this Section for a period [***]. 
 7.3 Exclusions from
Warranty. This warranty does not include Products that have defects or failures resulting from (a) CUSTOMER’s design of Products including, design functionality failures, , failures relating to the functioning of Products in the manner
for the intended purpose or in the specific CUSTOMER’s environment; (b) accident, disaster, neglect, abuse, or Customer’s negligent actions such as misuse, improper handling, testing, storage or installation including improper
handling in accordance with static sensitive electronic device handling requirements; (c) alterations, modifications or repairs by CUSTOMER or third parties without SANMINA-SCI’s prior written approval or (d) defective
CUSTOMER-provided test equipment or test software.  
 7.4 Remedy. THE SOLE REMEDY UNDER THIS WARRANTY SHALL BE
THE REPAIR, REPLACEMENT OR CREDIT FOR DEFECTS AS STATED ABOVE. THIS WARRANTY IS THE SOLE WARRANTY GIVEN BY SANMINA-SCI AND IS IN LIEU OF ANY OTHER WARRANTIES EITHER EXPRESS OR IMPLIED. SANMINA-SCI DOES NOT MAKE ANY WARRANTIES REGARDING
MERCHANTIBILITY, NONINFRINGEMENT, (OR SIMILAR LEGISLATION), OR FITNESS FOR A PARTICULAR PURPOSE, AND SPECIFICALLY DISCLAIMS ANY SUCH WARRANTY, EXPRESS OR IMPLIED. 

 

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

	8.	CUSTOMER FURNISHED EQUIPMENT AND COMPONENTS 

8.1 Customer-Furnished Items. CUSTOMER shall provide SANMINA-SCI with the Product design and related specifications, applicable
regulatory requirements, equipment, tooling, Components or documentation set forth in Exhibit C (collectively the “Customer-Furnished Items”). CUSTOMER shall deliver the Customer-Furnished Items to SANMINA-SCI in a timely manner.
Documentation (including BOM’s, drawings and artwork) shall be current and complete and maybe updated by Customer from time to time. 

8.2 Care of Customer-Furnished Items. All Customer-Furnished Items shall remain the property of CUSTOMER. However, while in
SANMINA_SCI’s custody and control, any and all such Customer Furnished Items will be covered under a broad form property insurance policy, a warehouseman’s liability policy and marine cargo policy in amounts to cover full replacement cost.
SANMINA-SCI shall clearly identify all Customer-Furnished Items by an appropriate tag and shall utilize such Customer-Furnished Items solely in connection with the manufacture of CUSTOMER’s Product. SANMINA-SCI agrees that it will not pledge,
encumber, use the Customer-Furnished Items as collateral, or permit any liens to be attached to the Customer-Furnished Items or use the Customer-Furnished Items for any such purposes without the written consent of Customer. SANMINA-SCI shall not
make or allow modifications to be made to Customer-Furnished Items without CUSTOMER’s prior written consent. SANMINA-SCI shall be responsible for reasonable diligence and care in the use and protection of any Customer-Furnished Items and
routine maintenance of any Customer-Furnished equipment, but shall not be responsible for repairs or replacements (including servicing and calibration to the equipment) unless such failure was caused by SANMINA-SCI’s negligence or willful
misconduct. All Customer-Furnished Items shall be returned to CUSTOMER at CUSTOMER’s expense upon request. SANMINA-SCI’s production and warranty obligations which require the utilization of the returned Customer-Furnished Items will cease
upon SANMINA-SCI’s fulfillment of CUSTOMER’s request. 
 8.3 Customer-Furnished Components. Customer-furnished
Components shall be handled in accordance with the applicable SANMINA-SCI manufacturing facility’s procedures regarding Customer-Furnished Material. 
  

	9.	INDEMNIFICATION AND LIMITATION OF LIABILITY 

9.1 SANMINA-SCI’s Indemnification. SANMINA-SCI shall indemnify, defend, and hold CUSTOMER and CUSTOMER’s affiliates,
shareholders, directors, officers, employees, contractors, agents and other representatives (the “Customer-Indemnified Parties”) harmless from all third party demands, claims, actions, causes of action, proceedings, suits, assessments,
losses, damages, liabilities, settlements, judgments, fines, penalties, interest, costs and expenses (including reasonable fees and disbursements of counsel) of every kind (each a “Claim,” and, collectively “Claims”)
(i) based upon personal injury or death or injury to property (other than damage to the Product itself, which is handled in accordance with Section 7 “Warranty”) to the extent any of the foregoing is caused by the negligent or willful
acts or omissions of SANMINA-SCI or its officers, employees, subcontractors or agents, and/or (ii) arising from or relating to any actual or alleged infringement or misappropriation of any patent, trademark, mask work, copyright, trade secret,
or any actual or alleged violation of any other intellectual property rights arising from or in connection with SANMINA-SCI’s manufacturing processes. 

9.2 CUSTOMER’s Indemnification. CUSTOMER shall indemnify, defend, and hold SANMINA-SCI and SANMINA-SCI’s affiliates,
shareholders, directors, officers, employees, contractors, agents and other representatives (the “SANMINA-SCI-Indemnified Parties”) harmless from all third party Claims (i) based upon personal injury or death or injury to property to
the extent any of the foregoing is caused by a defective Product, by the negligent or willful acts or omissions of CUSTOMER or its officers, employees, subcontractors or agents (except as otherwise result from SANMINA-SCI’s manufacturing
processes), and/or (ii) arising from or relating to any actual or alleged infringement or misappropriation of any patent, trademark, mask 

 

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 
work, copyright, trade secret or any actual or alleged violation of any other intellectual property rights arising from or in connection with the Customer’s designs or Specifications of the
Products, except to the extent that infringement occurs as a result of SANMINA-SCI’s manufacturing processes. 
 9.3
Procedure. A Party entitled to indemnification pursuant to this Section (the “Indemnitee”) shall promptly notify the other Party (the “Indemnitor”) in writing of any Claims covered by this indemnity. Promptly after receipt
of such notice, the Indemnitor shall assume the defense of such Claim with counsel reasonably satisfactory to the Indemnitee. If the Indemnitor fails, within a reasonable time after receipt of such notice, to assume the defense with counsel or, if a
direct or indirect conflict of interest exists between the Parties with respect to the Claim, the Indemnitee shall have the right to undertake the defense of such Claims, provided however that the Indemnitee shall have no right to compromise and
settlement such Claim for the account and at the expense of the Indemnitor. If the Claim is one of multiple claims in a lawsuit against Indemnitee, some of which claims may not be subject to the indemnity obligation of the Indemnitor, Indemnitee
may, at its sole discretion, elect to solely control the defense, settlement, adjustment or compromise of those claims for which is not subject to the Indemnitor’s indemnity obligations under this Section 9, in which event the Indemnitor
agrees to cooperate with Indemnitee’s sole control and provide any assistance as may be reasonably necessary for the defense, settlement, adjustment or compromise of any such controversy or proceedings. Notwithstanding the foregoing, if the
Indemnitee in its sole judgment so elects, the Indemnitee may also participate in the defense of such action by employing counsel at its expense, without waiving the Indemnitor’s obligation to indemnify and defend. The Indemnitor shall not
compromise any Claim (or portions thereof) or consent to the entry of any judgment without an unconditional release of all liability of the Indemnitee as to each claimant or plaintiff. 

9.4 Limitation of Liability. EXCEPT FOR BREACHES OF CONFIDENTIALITY OBLIGATIONS AND EXCEPT FOR AMOUNTS PAYABLE PURSUANT TO THE
PARTY’S INDEMNIFICATION OBLIGATIONS HEREOF, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR SPECIAL DAMAGES, OR ANY DAMAGES WHATSOEVER RESULTING FROM LOSS OF USE, DATA OR PROFITS,
EVEN IF SUCH OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. FOR THE PURPOSE OF THIS SECTION, BOTH LOST PROFITS AND DAMAGES RESULTING FROM VALUE ADDED TO THE PRODUCT BY CUSTOMER SHALL BE CONSIDERED CONSEQUENTIAL DAMAGES. EXCEPT FOR
BREACHES OF CONFIDENTIALITY OBLIGATIONS AND EXCEPT FOR AMOUNTS PAYABLE PURSUANT TO THE PARTY’S INDEMNIFICATION OBLIGATIONS HEREOF, IN NO EVENT SHALL EITHER PARTY’S LIABILITY FOR ALL CLAIMS ARISING OUT OF OR RELATING TO THIS AGREEMENT
EXCEED THE GREATER OF EITHER $[***] or [***]. THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. Notwithstanding the foregoing, the provisions of this Section shall not apply to limit
(i) Customer’s obligation for termination payments in accordance with section 10 (ii). THE LIMITATIONS SET FORTH IN THIS SECTION SHALL APPLY WHERE THE DAMAGES ARISE OUT OF OR RELATE TO THIS AGREEMENT. 

 

	10.	TERMINATION 

 10.1
Termination for Cause. Either Party may terminate this Agreement or an Order hereunder for default if the other Party materially breaches this Agreement; provided, however, no termination right shall accrue until thirty (30) days after
the defaulting Party is notified in writing of the material breach and has failed to cure or give adequate assurances of performance within the thirty (30) day period after notice of material breach. 

10.2 Termination for Convenience. Subject to Section 10.4, CUSTOMER may terminate this Agreement or an order hereunder
for any reason upon thirty (30) days’ prior 
  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 
written notice. Subject to Section 10.4, SANMINA-SCI may terminate this Agreement for any reason upon sixty (60) days’ notice, provided, however, that after such termination of the
Agreement, SANMINA-SCI shall continue to provide product to the Customer for a period mutually agreed to by both parties as may be needed to meet Customer’s contractual commitments with its customers. 

10.3 Termination by Operation of Law. This Agreement shall terminate should either Party (a) become insolvent; (b) enter
into or file a petition, arraignment or proceeding seeking an order for relief under the bankruptcy laws of its respective jurisdiction and such actions are not dismissed with thirty (30) days; (c) enter into a receivership of any of its
assets and such actions are not dismissed within thirty (30) days or (d) enter into a dissolution or liquidation of its assets or an assignment for the benefit of its creditors and such actions are not dismissed within thirty
(30) days. 
 10.4 Consequences of Termination. 

a. Termination for Reasons other than SANMINA-SCI’s Breach. In the event this Agreement or an Order hereunder is terminated
for any reason other than a breach by SANMINA-SCI (including but not limited to a force majeure or termination for convenience), CUSTOMER shall pay SANMINA-SCI, termination charges equal to (1) [***]; (2) [***]; and (3) [***]. The
foregoing statement of states the entire Liability of Customer and SANMINA-SCI’s sole remedy for termination for convenience by Customer or SANMINA-SCI. In no event shall Customer’s liability or any cancellation or termination of an
Order(s) or the Agreement exceed the price of the Order(s) cancelled hereof. 
 b. Termination Resulting from
SANMINA-SCI’s Breach. In the event CUSTOMER terminates this Agreement or any Order hereunder as a result of a breach by SANMINA-SCI, CUSTOMER shall pay SANMINA-SCI, termination charges equal to (1) [***]; (2) [***]; and
(3) [***]. In no event shall Customer’s payment to SANMINA-SCI’s under this section 10.4(b) constitute a waver by Customer of any kind to enforce any of the provisions of this Agreement or pursue any rights, remedies or options
available at law, equity or otherwise. 
  

	11.	QUALITY 

 11.1
Specifications. Product shall be manufactured by SANMINA-SCI in accordance with the Specifications and industry standard IPC-A-600 or IPC-A-610, as modified via written ECO’s in accordance with this Agreement. Neither Party shall make
any change to the Specifications, to any Inventory described therein, or to the Products (including, without limitation, changes in form, fit, function, design, appearance or place of manufacture of the Products or changes which would affect the
reliability of any of the Products) unless such change is made in accordance with Section 6.1. Notwithstanding the foregoing, SANMINA-SCI shall be permitted to make changes in its manufacturing process at any time, so long as such changes do
not affect the form, fit, or function of the Products. 
 11.2 Content of Specifications. The Specifications shall
include, but shall not be limited to (i) detailed electrical, mechanical, performance and appearance specifications for each model of Product, (ii) the BOM; (iii) tooling specifications, along with a detailed description of the
operation thereof, (iv) art work drawings, (v) Component specifications, (vi) Vendor cross references. 
 11.3
Components. SANMINA-SCI shall use in its production of Products such Components of a type, quality, and grade specified by CUSTOMER to the extent CUSTOMER chooses to so specify, and shall purchase Components only from Vendors appearing on
CUSTOMER’s approved vendor list (“AVL”); provided, however, that in the event SANMINA-SCI cannot purchase a Component from a Vendor on CUSTOMER’s AVL for any reason, SANMINA-SCI shall be able to purchase such Component from an
alternate Vendor, subject to CUSTOMER’s prior written approval, which approval shall not be unreasonably withheld or 
  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 
delayed. SANMINA-SCI shall use commercially reasonable efforts to manage all Vendors, but shall not be responsible for any Component (including the failure of any Component to comply with the
Specifications). SANMINA-SCI shall pass through Component warranties to the extent that they are transferable, as well as manage such warranties, as further specified in Section 7 above. 

11.4 Quality Specifications. SANMINA-SCI shall comply with the quality specifications set forth in its Quality Manual,
incorporated by reference herein, a copy of which is available from SANMINA-SCI upon request. 
 11.5 SANMINA-SCI agrees
(i) to properly inspect and test all Components and Product(s) to ensure that they meet the Specifications and any other mutually agreed quality requirements prior to delivery to Customer; (ii) to maintain inspection and test records of
the Components and Product, including without limitation, out-going quality level of the Product(s), and (iii) to provide to Customer for review all inspection and testing data and records upon Customer’s request. 

11.6 Inspection of Facility. Upon reasonable advance written notice and, upon SANMINA-SCI’s request the execution of an
appropriate nondisclosure agreement, CUSTOMER and its representatives, including Customer’s insurance carrier, may inspect any SANMINA-SCI facility and the Products and Components held by SANMINA-SCI for CUSTOMER at SANMINA-SCI’s
facilities during SANMINA-SCI’s regular business hours, provided that such inspection does not unduly affect SANMINA-SCI’s operations. CUSTOMER and its representatives shall observe all security and handling measures of SANMINA-SCI while
on SANMINA-SCI’s premises. CUSTOMER and its representatives acknowledge that their presence on SANMINA-SCI’s property is at their sole risk. Customer’s inspection of the Products and Components at SANMINA-SCI’s facility shall in
no way be considered Customer’s acceptance of such Products or Components nor a waiver of Customer’s right to do later perform incoming inspection of the Products or Components. 

 

	12.	FORCE MAJEURE 

 12.1
Force Majeure Event. For purposes of this Agreement, a “Force Majeure Event” shall mean the occurrence of unforeseen circumstances beyond a Party’s control and without such Party’s negligence or intentional misconduct,
including, but not limited to, any act by any governmental authority, act of war, natural disaster, strike, boycott, embargo, shortage, riot, lockout, labor dispute, civil commotion. 

12.2 Notice of Force Majeure Event. Neither Party shall be responsible for any failure to perform due to a Force Majeure Event
provided that such Party gives notice to the other Party of the Force Majeure Event as soon as reasonably practicable, but not later than five (5) days after the date on which such Party knew or should reasonably have known of the commencement
of the Force Majeure Event, specifying the nature and particulars thereof and the expected duration thereof; provided, however, that the failure of a Party to give notice of a Force Majeure Event shall not prevent such Party from relying on this
Section except to the extent that the other Party has been prejudiced thereby. 
 12.3 Termination of Force Majeure
Event. The Party claiming a Force Majeure Event shall use reasonable efforts to mitigate the effect of any such Force Majeure Event and to cooperate to develop and implement a plan of remedial and reasonable alternative measure to remove the
Force Majeure Event; provided, however, that neither Party shall be required under this provision to settle any strike or other labor dispute on terms it considers to be unfavorable to it. Upon the cessation of the Force Majeure Event, the Party
affected thereby shall immediately notify the other Party of such fact, and use its best efforts to resume normal performance of its obligations under the Agreement as soon as possible. 

 

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 12.4 Limitations. Notwithstanding that a Force Majeure Event otherwise exists, the
provisions of this Section shall not excuse (i) any obligation of either Party, including the obligation to pay money in a timely manner for Product actually delivered or other liabilities actually incurred, that arose before the occurrence of
the Force Majeure Event causing the suspension of performance; or (ii) any late delivery of Product, equipment, materials, supplies, tools, or other items caused solely by negligent acts or omissions on the part of such Party. 

 

	13.	CONFIDENTIALITY AND NON-SOLICITATION OF EMPLOYEES 

13.1 Definitions. For the purpose of this Agreement, 

(a) “Confidential Information” may include but is not limited to information (in any form or media) regarding a Party’s
customers, prospective customers (including lists of customers and prospective customers), methods of operation, engineering methods and processes (include, but not limited to manufacturing processes or any information which may be obtained by a
Party by reverse engineering, decompiling or examining any software or hardware provided by the other Party under this Agreement), programs and databases, patents and designs, billing rates, billing procedures, vendors and suppliers, business
methods, finances, management, or any other business information relating to such Party (whether constituting a trade secret or proprietary or otherwise) which has value to such Party and is treated by such Party as being confidential;
provided, however, that Confidential Information does not include information that (i) is known to the other Party without any restriction on use or disclosure or without any obligation of confidentiality prior to receipt from the
Disclosing Party hereunder, which knowledge shall be evidenced by written records, (ii) is independently developed without use or reference to any Confidential Information, as evidenced by written records, (iii) is or becomes in the public
domain through no breach of this Agreement, or (iv) is received from a third party without breach of any obligation of confidentiality as evidenced by written records. Confidential Information shall also include information obtained or
ascertained by Receiving Party as a result of any visit to any facility occupied by Disclosing Party or by third party which the Disclosing Party has a contractual, legal or fiduciary obligation of confidentiality to said party, whether or not
protectible by patent, copyright or other laws 
 (b) “Person” shall mean and include any individual, partnership,
association, corporation, trust, unincorporated organization, limited liability company or any other business entity or enterprise. 

(c) “Representative” shall mean a Party’s employees, agents, or representatives, including, without limitation, financial
advisors, lawyers, accountants, experts, and consultants. 
 13.2 Nondisclosure Covenants. 

(a) In connection with this Agreement, each Party (the “Disclosing Party”) may furnish to the other Party (the “Receiving
Party”) or its Representatives certain Confidential Information. For the term of this Agreement and for a period of five (5) years from the date of the termination of this Agreement, the Receiving Party (a) shall maintain as
confidential all Confidential Information disclosed to it by the Disclosing Party, (b) shall not, directly or indirectly, disclose any such Confidential Information to any Person other than (i) those Representatives of the Receiving Party
whose duties justify the need to know such Confidential Information and then only after each Representative has agreed to be bound by this Confidentiality Agreement and clearly understands his or her obligation to protect the confidentiality of such
Confidential Information and to restrict the use of such Confidential Information or (ii) if SANMINA-SCI is the Receiving Party, a third party Vendor for the purpose of obtaining price quotations, provided that SANMINA-SCI shall cause the
Vendor to agree to this Confidentiality Agreement and protect the confidentiality of such Confidential Information and to restrict the use of such Confidential Information, and (c) shall treat such Confidential Information with the same degree
of care as it treats its own Confidential Information (but in no case with less than a reasonable degree of care). 
  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 (b) The disclosure of any Confidential Information is solely for the purpose of enabling
each Party to perform under this Agreement, and the Receiving Party shall not use any Confidential Information disclosed by the Disclosing Party for any other purpose. 

(c) Except as otherwise set forth in this Agreement, all Confidential Information supplied by the Disclosing Party shall remain the
property of the Disclosing Party, and will be promptly returned by the Receiving Party upon receipt of written request therefore. 

(d) If the Receiving Party or its Representative is requested or becomes legally compelled to disclose any of the Confidential
Information, it will provide the Disclosing Party with prompt written notice. If a protective order or other remedy is not obtained, then only that part of the Confidential Information that is legally required to be furnished will be furnished, and
reasonable efforts will be made to obtain reliable assurances of confidentiality. 
 13.3 Non-Solicitation of Employees.
During the term of this Agreement and for a period of two (2) years thereafter, neither Party shall directly or indirectly solicit, recruit or hire (or attempt to solicit, recruit or hire) any of the other Party’s employees; provided,
however, that this shall not prohibit a Party from (a) advertising for open positions provided that such advertisements are not targeted solely at the employees of the other Party; (b) or employing any individual who initiates contact with
such Party on his or her own initiative, whether in response to an advertisement or otherwise. 
 13.4 Injunctive Relief
Authorized. Any material breach of this Section by a Party or its Representatives may cause irreparable injury and the non-breaching Party may be entitled to equitable relief, including injunctive relief and specific performance, in the
event of a breach. The above will not be construed to limit the remedies available to a Party. In addition, the prevailing Party will be entitled to be reimbursed for all of its reasonable attorneys’ fees and expenses at all levels of
proceedings and for investigations, from the non-prevailing Party. 
 13.5 No Publicity. Each Party agrees not to
publicize or disclose the existence or terms of this Agreement to any third party without the prior consent of the other Party except as required by law (in which case, the Party seeking to disclose the information shall give reasonable notice to
the other Party of its intent to make such a disclosure). Neither Party shall make any press release or similar public statement without the prior consent of the other Party. 

 

	14.	INSURANCE 

 Without in
anyway limiting SANMINA-SCI’s indemnification obligations, SANMINA-SCI agrees to maintain during the term of this Agreement (a) workers’ compensation insurance as prescribed by the law of the nation, state, territory or providence in
which SANMINA-SCI’s services are performed; (b) employer’s liability insurance with limits of at least $500,000 per occurrence; (c) commercial automobile liability insurance if the use of motor vehicles is required in the
performance of this contract, with limits of at least $1,000,000 for bodily injury and property damage for each occurrence; (d) commercial general liability insurance, including blanket contractual liability and broad form property damage, with
limits of not less than $1,000,000 combined single limit for personal injury and property damage for each occurrence; and (e) commercial general liability insurance endorsed to include products liability and completed operations coverage with
limits not less than $1,000,000 for each occurrence; (f) errors and omissions insurance covering its acts, errors and omissions in connection with the services provided under this Agreement, with limits of not less than $500,000 per occurrence
or per claim and $1,000,000 in the annual aggregate; (g) warehouseman’s liability policy to cover the full value of products held on behalf of CUSTOMER; and (h) Cargo-Marine insurance policy to cover the full value and risk `of all

  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 
shipments to CUSTOMER SANMINA-SCI shall furnish to CUSTOMER upon request certificates or evidence of the foregoing insurance indicating the amount and nature of such coverage and the expiration
date of each policy. CUSTOMER’S receipt or review of such certificates or evidence of insurance shall not relieve SANMINA-SCI of its obligations to maintain insurance policies as outlined herein. Each Party agrees that it, its insurer(s) and
anyone claiming by, through, under or in its behalf shall have no claim, right of action or right of subrogation against the other Party and the other Party’s affiliates, directors, officers, employees and customers based on any loss or
liability insured against under the insurance required by this Agreement. 
  

	15.	BUSINESS CONTINUITY PLAN 

 SANMINA-SCI
shall have in place a business continuity plan, as regularly updated as required, that will ensure that SANMINA-SCI is able to perform under the Agreement and to continue to provide Products and services to Customer when the manufacture or delivery
of Products is interrupted for any reason outside of SANMINA-SCI’s reasonable control (“BCP”). Upon Customer’s request, SANMINA-SCI will provide and a copy of the BCP plan to Customer for review. 

 

	16.	MISCELLANEOUS 

 16.1
Integration Clause. This Agreement (including the Exhibits and Schedules to this Agreement) constitutes the entire agreement of the Parties, superseding all previous Agreements covering the subject matter. This Agreement shall not be changed
or modified except by written agreement, specifically amending, modifying and changing this Agreement, signed by SANMINA-SCI and an authorized representative of the CUSTOMER. 

16.2 Order of Precedence. All quotations, Orders, acknowledgments and invoices issued pursuant to this Agreement are issued for
convenience of the Parties only and shall be subject to the provisions of this Agreement and the Exhibits hereto. When interpreting this Agreement, precedence shall be given to the respective parts in the following descending order: (a) this
Agreement; (b) Schedules and Exhibits to this Agreement; and (c) if Orders are used to release product, those portions of the Order that are not pre-printed and which are accepted by SANMINA-SCI. The Parties acknowledge that (y) the
preprinted provisions on the reverse side of any such quotation, Order, acknowledgment or invoice and (z) all terms other than the specific terms set forth in Section 4.1(a)(i)-(iv) shall be deemed deleted and of no effect whatsoever.
No modification to this Agreement, the Exhibits or any Order shall be valid without the prior written consent of the Purchase Agreement Coordinators of SANMINA-SCI and CUSTOMER. 

16.3 Assignment. Neither this Agreement nor any rights or obligations hereunder shall be transferred or assigned by either Party
without the written consent of the other Party, which consent shall not be unreasonably withheld or delayed. This Agreement (a) may be assigned in whole or in part by either Party to any Affiliate of such Party provided that such Party remains
secondarily liable under this Agreement and (b) may be assigned by Customer to a successor in interest upon any reorganization, change of control, merger, acquisition, or sale of all or substantially all of the assets of the assigning party.
Notwithstanding the foregoing, either Party may assign its right to payment to a third party without the need for consent from the other Party. 

 

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 16.4 Notices. Wherever one Party is required or permitted or required to give written
notice to the other under this Agreement, such notice will be given by hand, by certified U.S. mail, return receipt requested, by overnight courier, or by fax and addressed as follows: 

 

			
	If to CUSTOMER:	  	with a copy to:
		
	Symmetricom, Inc.	  	Symmetricom, Inc.
	2300 Orchard Parkway,	  	2300 Orchard Parkway
	San Jose, CA 95131	  	San Jose, CA 95131
	Attn: VP – Supply Chain	  	Attn: Legal
	Fax: 408-428-	  	
		
	If to SANMINA-SCI:	  	with a copy to:
		
	SANMINA-SCI Corporation	  	SANMINA-SCI Corporation
	2700 N. First Street	  	2700 N. First Street
	San Jose, California 95134	  	San Jose, California 95134
	Att’n: EVP, Sales	  	Att’n: Vice President & Corporate Counsel
	Phone: (408) 964-3600	  	Phone: (408) 964-3600
	Fax: (408) 964-3636	  	Fax: (408) 964-3636

 All such notices shall be effective
upon receipt. Either Party may designate a different notice address from time to time upon giving ten (10) days’ prior written notice thereof to the other Party. 

16.5 Disputes/Choice of Law/Attorneys Fees. The Parties shall attempt to resolve any disputes between them arising out of this
Agreement through good faith negotiations. In the event the Parties cannot resolve a dispute, the Parties acknowledge and agree that the state courts of Santa Clara County, California and the federal courts located in the Northern District of the
State of California shall have exclusive jurisdiction and venue to adjudicate any and all disputes arising out of or in connection with this Agreement. The Parties consent to the exercise by such courts of personal jurisdiction over them and each
Party waives any objection it might otherwise have to venue, personal jurisdiction, inconvenience of forum, and any similar or related doctrine. This Agreement shall be construed in accordance with the substantive laws of the State of California
(excluding its conflicts of laws principles). The provisions of the United Nations Conventions on Contracts for the International Sale of Goods shall not apply to this Agreement. The prevailing Party shall be entitled to recover its costs and
reasonable attorney’s fees from the non-prevailing Party in any action brought to enforce this Agreement. 
  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the Effective
Date, by their officers, duly authorized. 
  

									
	SANMINA-SCI CORPORATION	 		 	CUSTOMER
					
	By:	 	 /s/    George
Korson        
	 		 	By:	 	 /s/    Gregory P.
Ruebusch        

		 	Signature	 		 		 	Signature
					
		 	 George Korson
	 		 		 	 Gregory P. Ruebusch

		 	Typed Name	 		 		 	Typed Name
					
		 	 Vice President
	 		 		 	 EVP Operations

		 	Title	 		 		 	Title
					
		 	 March 30, 2010
	 		 		 	 March 22, 2010

		 	Date	 		 		 	Date

  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 INDEX 

1. TERM 
 2. PRICING 

3. PAYMENT TERMS 
 4. PURCHASE ORDERS/ FORECAST/
RESCHEDULE 
 5. DELIVERY AND ACCEPTANCE 

6. CHANGES 
 7. WARRANTY 

8. CUSTOMER FURNISHED EQUIPMENT AND COMPONENTS 

9. INDEMNIFICATION AND LIMITATION OF LIABILITY 

10. TERMINATION 
 11. QUALITY 

12. FORCE MAJEURE 
 13. CONFIDENTIALITY AND
NON-SOLICITATION OF EMPLOYEES 
 14. INSURANCE 

15. MISCELLANEOUS 
 EXHIBITS 

A. PRICES 
 B. LONG LEAD-TIME COMPONENTS

 C. CUSTOMER FURNISHED EQUIPMENT, COMPONENTS AND DOCUMENTATION 
  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and Exchange
Commission. 

 EXHIBIT A 

PRICING 
  

					
	Product	  	Quantity	  	Price
			
		  	[***]	  	

  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] 3 pages listing prices have been omitted and filed separately with the Securities and Exchange Commission.

 EXHIBIT B 

LONG LEAD-TIME COMPONENTS 

[***] 
  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] 12 pages listing Long Lead-time Components have been omitted and filed separately with the Securities and
Exchange Commission. 

 EXHIBIT C 

CUSTOMER FURNISHED EQUIPMENT, COMPONENTS, AND DOCUMENTATION 

[***] 
  

					
	Rev 2/10/09	 	CONFIDENTIAL	 	

 [***] 108 pages of invoices listing Customer Furnished Equipment, Components, and Documentation have been omitted and
filed separately with the Securities and Exchange Commission. 

 Prepaid Program 

Addendum 1 to the Manufacturing Service Agreement 

Between 

Sanmina-SCI and Symmetricom, Inc. 

This Addendum 1 (“Addendum”) is made and entered into on September 19, 2009, between Sanmina-SCI Corporation, on behalf of itself and its
affiliates and subsidiaries (“Company”) and Symmetricom, Inc., on behalf of itself and its affiliates and subsidiaries (“Customer”). This Addendum is subject to the terms and conditions of the “Letter of Agreement”
dated June 30, 2008, as superseded by the “Manufacturing Services Agreement”, between Company and Customer, dated September     , 2009 (collectively, the “MSA”), except in the event of a conflict
between the terms and conditions of this Addendum and the terms of the MSA, the terms of this Addendum shall control. 
  

	I.	Definition of Terms: 

 Excess
Inventory: Inventory that Company has on hand which has been ordered, manufactured or acquired in support of Customer requirements, and is deemed to be excess in accordance with the terms set forth in the MSA. 

Obsolete Inventory: Inventory that Company has on hand, which has been ordered, manufactured, or acquired in support of Customer requirements, and is
deemed to be obsolete in accordance with the terms set forth in the MSA. 
 Prepaid Inventory: Inventory that is held by Company for Customer
under this prepaid program. 
 Company Inventory: Inventory bought and owned by Company in support of Customer Requirements as set forth in the
MSA. 
 Customer Inventory: Inventory that has been bought and is owned by Customer, and resides in Customer’s facility/control.

  

	II.	Purpose: 

 This Amendment sets
forth the terms for the Customer Prepaid Program, which enables two types of pre-paid inventory processes as follows: 
  

	 	a.	Prepaid Inventory process for Company Inventory, as further set forth in Section III below. 

 

	 	b.	Prepaid Inventory process for Customer Inventory, as further set forth in Section IV below. 

 

 CONFIDENTIAL – May not be disclosed outside of Sanmina-SCI and Symmetricom, Inc.,
except with the prior written consent of the contracting parties 
 [***] Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission 
 Page 1 of 4 

	III.	Prepaid Inventory Process for Company Inventory: 

Within [***] upon completion of the Excess and Obsolete Inventory review process as defined in the terms of the MSA, and the parties have determined that
the Excess and Obsolete Inventory is to be moved into Prepaid Inventory (hereafter “Mutually Agreed Excess”), the parties will: 
  

	 	1.	Compare the prior quarter’s Prepaid Inventory reserve account with the new Mutually Agreed Excess amount. 

 

	 	2.	If the new Mutually Agreed Excess amount is greater than the Prepaid Inventory reserve account, then Customer shall, within [***], pay the difference between the
Mutually Agreed Excess amount and the Prepaid Inventory amount to Company, who shall credit the Prepaid Price (Defined in Section IV, below) to the Prepaid Inventory reserve account. 

 

	 	3.	If the new Mutually Agreed Excess amount is less than the Prepaid Inventory reserve account, then Company shall, within [***], refund the amount in difference between
these two to Customer. 

  

	IV.	Prepaid Inventory Process for Customer Inventory: 

When Customer Inventory has been identified by Customer as inventory that is to be moved into the prepaid program, the following process is to be
followed: 
  

	 	1.	Customer shall create a list of inventory to be transferred, from any Customer facility to Company’s facility under the prepaid program. 

 

	 	2.	Customer and Company shall perform a joint audit of the Prepaid Inventory to determine: 

 

	 	a.	Technical or commercial viability of the inventory 

  

	 	b.	Quantity 

  

	 	c.	Approved Manufacturers in accordance with Customer’s AML 

  

	 	3.	[***] 

  

	 	4.	Company shall then purchase the Prepaid Inventory by issuing a purchase order (“PO”) to Customer for said inventory at [***] and hold the inventory in a
prepaid account for Customer’s benefits. 

  

	 	5.	Customer will at the same time issue a PO to Company for the agreed upon amount of Prepaid Inventory. 

 

	 	6.	Upon receipt of the POs by Company and Customer, respectively, each party shall send a corresponding invoice to the other party. 

 

	 	7.	Payment shall be made by each party concurrently to the other party’s account no later than thirty (30) days from date of invoice. 

 

	 	8.	Title of the Prepaid Inventory shall remain with Company after payment is received from the Customer, except that at all time the Prepaid Inventory shall be held by
Company for the benefit of Customer until used or consumed by Customer or disposed of in accordance with the terms of this program. 

  

 CONFIDENTIAL – May not be disclosed outside of Sanmina-SCI and Symmetricom, Inc.,
except with the prior written consent of the contracting parties 
 [***] Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission 
 Page 2 of 4 

	V.	Business Process: 

  

	 	1.	Company assumes risk of loss for all Prepaid Inventory held at a Company facility. 

 

	 	2.	If Customer desires to purchase Excess Inventory from Company that is in the prepaid program, Customer will issue a PO to Company for said inventory.

  

	 	3.	Company shall maintain Prepaid Inventory in a “Net-able Inventory location on Oracle and to use commercially reasonable effort to first use and consume the
inventory under this prepaid program to fulfill Customer’s orders and requirements as set forth in the MSA prior to purchasing inventory from outside suppliers. When any inventory is transferred from the prepaid program into normal inventory
for Customer’s requirements under the MSA, it will be transacted at the Prepaid Price without any Company mark-up. 

  

	 	4.	The parties agree that Company may transfer the Prepaid Inventory, in whole or in part, to other Company sites in order to produce Customer product without
Customer’s prior consent, except for Prepaid Inventory that is identified as strategic inventory pursuant to paragraph 5 below. 

  

	 	5.	Prepaid Inventory that is identified as strategic inventory (end of life, last time buy, proprietary to Customer, ITAR regulated) may not be transferred to or used for
any third party or for non-Customer usage without Customer’s prior written consent. 

  

	 	6.	If Customer directs Company to dispose of any of the inventory in the prepaid program, the Company will systematically scrap and physically scrap identified inventory
within the same accounting period per Customer’s direction. Customer will issue a PO to Company for said inventory. 

  

	 	7.	Customer reserves the right, upon 30 days notice to perform a process audit of Prepaid Inventory at Company’s facility. 

 

	 	8.	[***] 

  

	VI.	Liens; Bankruptcy Proceeding: 

  

	 	1.	Company hereby acknowledges that the Prepaid Inventory identified under this Addendum has been prepaid by Customer. Company agrees that it will not pledge,
encumber, use the Prepaid Inventory as collateral, or permit any liens to be attached to the Prepaid Inventory or use the Prepaid Inventory for any such purposes without the written consent of Customer. Company further agrees to execute any
other necessary document to further protect Customer’s interest in the Inventory, including UCC-1 filing regarding the Prepaid Inventory 

  

 CONFIDENTIAL – May not be disclosed outside of Sanmina-SCI and Symmetricom, Inc.,
except with the prior written consent of the contracting parties 
 [***] Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission 
 Page 3 of 4 

	 	2.	In the event Company files a petition under the U.S. Bankruptcy Code or is the subject of involuntary bankruptcy proceeding under such Code, the parties hereby
stipulate to the lifting of the automatic stay in effect and relief from such stay. 

 IN WITNESS WHEREOF, the Parties
hereto have caused this Addendum to be executed as of the Effective Date, by their officers, duly authorized. 
  

									
	SANMINA-SCI CORPORATION	 		 	SYMMETRICOM, INC.
					
	By:	 	 /s/    Michael
Sparacino        
	 		 	By:	 	 /s/    Justin
Spencer        

		 	Signature	 		 		 	Signature
					
		 	 Michael Sparacino
	 		 		 	 Justin Spencer

		 	Typed Name	 		 		 	Typed Name
					
		 	 Vice-President
	 		 		 	 CFO

		 	Title	 		 		 	Title
					
		 	 9/18/09
	 		 		 	 9/18/09

		 	Date	 		 		 	Date

  

 CONFIDENTIAL – May not be disclosed outside of Sanmina-SCI and Symmetricom, Inc.,
except with the prior written consent of the contracting parties 
 [***] Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission 
 Page 4 of 4 

 Addendum 2 to the Letter of Agreement 

Between 

Sanmina-SCI and Symmetricom, Inc. 

This Addendum 2 (“Addendum”) is made and entered into on April 2, 2010, between Sanmina-SCI Corporation, on behalf of itself and its
affiliates and subsidiaries (“Company”) and Symmetricom, Inc., on behalf of itself and its affiliates and subsidiaries (“Customer”). This Addendum is subject to the terms and conditions of the Manufacturing Service Agreement
(MSA) between Company and Customer, dated March 12, 2010, except in the event of a conflict between the terms and conditions of this Addendum and the terms of MSA, the terms of the Addendum shall control. 

 

	I.	Definition of terms: 

Company: Refers to Sanmina-SCI Corporation 

Customer: Refers to Symmetricom, Inc. 

Company’s New Hampshire facility: refers to both Manchester and Derry locations in New Hampshire. 

Customer’s Puerto Rico facility: refers to Aguadilla manufacturing facility in Puerto Rico. 

Product and Services: [***] 
 Closing
of Facility: This is accomplished when all manufacturing process and products have been transferred and are actively being produced in New Hampshire. 
  

	II.	Purpose: 

 This Addendum sets forth
the terms and conditions for the transfer management project which will result in the closing of the Customer’s Puerto Rico facility. The products and services of the Customer’s manufacturing facility will be transferred to the
Company’s facility in New Hampshire. In consideration for the management of this project, the Company shall be paid a transfer management fee (the “Fee”) of [***] All costs claimed by Company are to be submitted to Customer for
review. 
  

	III	Program Overview: 

  

	 	1.	On April 6, 2010 Customer will announce the closing of its manufacturing facility in Puerto Rico to the public. 

 

	 	2.	On April 12, 2010 Company shall bring a transfer team to the Customer’s manufacturing facility in Puerto Rico. 

 

	 	3.	The Company’s transfer team which will consist of manpower resources that will reside in Puerto Rico and travel as needed to enable the transfer of production from
Puerto Rico to New Hampshire. This transfer team will consist of employees of Company to cover the functional areas of responsibility matched with functional responsibilities in Customer’s site in Puerto Rico. 

 

	 	4.	Functional areas are to include: 

  

	 	a.	[***] 

  

	 	b.	[***] 

  

	 	i.	[***] 

  

	 	ii.	[***] 

  

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and
Exchange Commission. 

	 	iii.	[***] 

  

	 	iv.	[***] 

  

	 	v.	[***] 

  

	 	vi.	[***] 

  

	 	vii.	[***] 

  

	 	c.	[***] 

  

	 	d.	[***] 

  

	 	5.	The transfer team is intended to learn the processes performed in Puerto Rico and then transfer said product and processes to New Hampshire. 

 

	 	6.	Prior to transfer, Company will re-quote all assemblies using the pre-agreed manufacturing rates for the New Hampshire site. 

 

	 	7.	The Company will be responsible for managing the transfer of Symmetricom products currently manufactured at the Puerto Rico facility to Company’s New Hampshire
site. Customer will provide at least one Management representative on site at all times to assist Company with decisions and oversight questions that may arise. Any critical decisions would be mutually agreed to by both Company and Customer, with
final responsibility for decisions and oversight residing with Customer. 

  

	 	8.	With the aid of and under the authority of Symmetricom employees and outside resources the Company transfer team will use it best efforts to support a consistent
revenue flow during the transfer period while transferring product from Puerto Rico to New Hampshire to meet Symmetricom customer product delivery requests. 

 

	 	9.	As the transfer project progresses the Company will work with Customer management and representatives to reduce the headcount at Customer’s plant and use best
efforts to identify areas where expenses can be reduced. 

  

	 	10.	All products and services are to be transferred to the Company’s facility in New Hampshire no later than [***]. 

 

	 	11.	At the conclusion of the [***] period all operations being performed in Customer’s Puerto Rico facility will be actively performed to Customer’s quality
standards in Company’s facility in New Hampshire. 

  

	IV.	Terms of Agreement: 

  

	 	1.	The Company’s Fee, will be paid by Symmetricom on a [***] basis. 

  

	 	2.	The Fee shall be paid in equal installments at [***] The first [***] installment is to be paid on [***]. 

 

	 	3.	[***], shall be withheld by Customer until project completion. Any Fee amounts below or in excess of [***] will be settled upon completion of the project.

  

	 	4.	The transfer of manufacturing equipment, inventory, and other items to be used in the manufacture of Symmetricom product by Company at Company’s New Hampshire site
shall be paid by [***]. 

  

	 	5.	[***] shall be administered and paid by Symmetricom. 

  

	V.	Dispute Resolution 

 Prior to
initiating any legal proceeding, the parties shall attempt in good faith to resolve any dispute arising out of or relating to this Program promptly by negotiation between executives who have authority to settle the controversy and who are at a
higher level of management than the persons with direct responsibility for administration of this Program within thirty (30) days from date of receipt notice to enter into negotiation or a longer time as mutually agreed to by the parties. All
communications and negotiations pursuant to this clause are confidential and shall be treated as compromise and settlement negotiations and shall be protected by the applicable rules of evidence. 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the Effective Date, by their officers, duly authorized.

  

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and
Exchange Commission. 

									
	SANMINA-SCI CORPORATION	 		 	SYMMETRICOM, INC.
					
	By:	 	 /s/    Frank
Morrone        
	 		 	By:	 	 /s/    Justin
Spencer        

		 	Signature	 		 		 	Signature
					
		 	 Frank Morrone
	 		 		 	 Justin Spencer

		 	Typed Name	 		 		 	Typed Name
					
		 	 Exec. Vice Pres.
	 		 		 	 Chief Financial Officer

		 	Title	 		 		 	Title
					
		 	 April 2, 2010
	 		 		 	 April 2, 2010

		 	Date	 		 		 	Date

  

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and
Exchange Commission. 

 Amendment 1 to Addendum 2 to the Agreement 

Between 

Sanmina-SCI and Symmetricom, Inc. 

This Amendment 1 (“Amendment”) is made by and between Sanmina-SCI Corporation, on behalf of itself and its affiliates and subsidiaries
(“Company”) and Symmetricom, Inc., on behalf of itself and its affiliates and subsidiaries (“Customer”). 
 Whereas,
Company and Customer entered into a Manufacturing Service Agreement (MSA) dated March 12, 2010; 
 Whereas, Company and Customer
entered into Addendum 1, dated September 19, 2009, to add Prepaid Inventory Program ordering process and inventory management to the MSA; 

Whereas, Company and Customer entered into Addendum 2, dated April 2, 2010, to add transition project management services to be provided by
Company in connection with the closure of Customer’s Puerto Rico facility; 
 Whereas, Company and Customer desire to amendment the
payment terms in Addendum 2 
 Now therefore, in consideration of the mutual covenants and obligations herein, the Parties agree as
follows: 
  

	1.	The Fee payable by Customer pursuant to Section IV (2) of Addendum 2 is hereby amended and replaced as follows: 

 

																	
		  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 Fee
	  	$	[***	] 	 	$	[***	] 	 	$	[***	] 	 	$	[***	] 
	 Holdback
	  	$	[***	] 	 	$	[***	] 	 	$	[***	] 	 	$	[***	] 
					
	 Net Payment Due
	  	$	[***	] 	 	$	[***	] 	 	$	[***	] 	 	$	[***	] 

  

	2.	The MSA together with Addendum 1 through Addendum 2 and this Amendment 1 constitute the entire agreement between the Parties hereto with respect to the subject matter
hereof. In the event of a conflict between the terms and conditions of this Amendment and the terms of the Addendums and the MSA with respect to the subject matter hereof, the terms of this Amendment shall control 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the Effective Date, by their officers, duly authorized.

  

									
	SANMINA-SCI CORPORATION	 		 	SYMMETRICOM, INC.
					
	By:	 	 /s/ Jose A. Carrasquillo
	 		 	By:	 	 /s/ Justin Spencer

	Name:	 	Jose A. Carrasquillo	 		 	Name:	 	Justin Spencer
	Title:	 	SVP	 		 	Title:	 	Chief Financial Officer
					
	Date:	 	5/25/10	 		 	Date:	 	5/20/10

  

 [***] Confidential portions of the exhibit have been omitted and filed separately with the Securities and
Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]